

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 28 July 1999 (28.07.99)	
<b>International application No.</b> PCT/CA98/00992	<b>Applicant's or agent's file reference</b> CG/11168.85
<b>International filing date</b> (day/month/year) 26 October 1998 (26.10.98)	<b>Priority date</b> (day/month/year) 24 October 1997 (24.10.97)
<b>Applicant</b> GEORGES, Elias et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

20 May 1999 (20.05.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

P. Regis

Telephone No.: (41-22) 338.83.38

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>CG/11168.85</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/CA 98/00992</b>	International filing date (day/month/year) <b>26/10/1998</b>	(Earliest) Priority Date (day/month/year) <b>24/10/1997</b>
Applicant <b>McGILL UNIVERSITY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

**P-40/ANNEXIN I AND RELATED PROTEINS AND THEIR ROLE I MULTIDRUG RESISTANCE**

5. With regard to the **abstract**,

the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.

6b



None of the figures.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference CG/11168.85		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA98/00992	International filing date (day/month/year) 26/10/1998	Priority date (day/month/year) 24/10/1997	
International Patent Classification (IPC) or national classification and IPC C12N15/12			
Applicant McGILL UNIVERSITY et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 10 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 7 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 20/05/1999	Date of completion of this report 09.03.00
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Nichogiannopoulou, A Telephone No. +49 89 2399 8054 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/00992

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-13,15-36 as originally filed

14 as received on 23/02/2000 with letter of 21/02/2000

### Claims, No.:

1-29 as received on 23/02/2000 with letter of 21/02/2000

### Drawings, sheets:

1/17-17/17 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**see separate sheet**

## II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:
- ☐ copy of the earlier application whose priority has been claimed.
  - ☐ translation of the earlier application whose priority has been claimed.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/00992

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 20-23 and 26-29, as far as they concern *in vivo* methods.

because:

- ☒ the said international application, or the said claims Nos. 20-23 and 26-29, as far as they concern *in vivo* methods relate to the following subject matter which does not require an international preliminary examination (*specify*):

**see separate sheet**

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA98/00992

- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.
2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☒ not complied with for the following reasons:
- see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☒ all parts.
- ☐ the parts relating to claims Nos. .

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims 6, 7, 12, 15-29
	No:	Claims 1-5, 8-11, 13, 14
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-29
Industrial applicability (IA)	Yes:	Claims 1-19, 24, 25
	No:	Claims

### 2. Citations and explanations

**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA98/00992

---

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/CA98/00992

**Re Item I**

**Basis of the report**

1. This opinion was established based on the application documents and the written sequence listing pages 1-7.
2. The amendments filed with the letter of 21.02.2000 are formally allowable under Article 34(2)(b) PCT because they do not introduce subject-matter extending beyond the content of the application as filed.

**Re Item II**

**Priority**

1. The following document was published prior to the international filing date but later than the priority date claimed (P-document):  
  
P1: CAROLLO, M. et al.: 'Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumour PC-3 cells are mediated by lipocortin I' ONCOLOGY RESEARCH, (July 1998), 10: 245-54
2. The priority document pertaining to the present application was not available at the time of establishing this first written opinion. Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document (24.10.1997). If it later turns out that this assumption is incorrect, P1 will become relevant to the assessment of whether the present application satisfies the criteria set forth in Article 33(2) and (3) PCT.



**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. Claims 20-23 and 26-29 -as far as they concern *in vivo* methods- relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Re Item IV**

**Lack of unity of invention**

1. The IPEA is of the opinion that the present application lacks unity under the terms of Rule 13.1 PCT. The present application relates to any and all members of the Annexin family and their implication in multidrug resistance (MDR). Since Annexin I and II have already been implicated in MDR (see D3 and D4 below), no common inventive concept exists unifying the individual Annexins as claimed in the present invention.

This objection is currently not being pursued. Should the application enter the European phase, an objection under the corresponding EPC article will be raised.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Reference is made to the following documents:

D1: WO 86 04094 A (BIOGEN) 17 July 1986

D2: HORSEMAN, N.D. et al.: 'Cell and species distribution of prolactin-inducible Annexin I mRNA' GEN. AND COMP. ENDOCRINOL., (1992), 85: 405-14

D3: BHUSHAN, A. & TRITTON, T.R.: 'Increased tyrosine phosphorylation of lipocortin I in multidrug resistant Sarcoma 180 cells.' PROC. AACR, (1991), 32: 362, Abstract 2148

D4: COLE, S.P.C. et al.: 'Elevated expression of Annexin II in a multidrug resistant small cell lung cancer cell.' BR. J. CANCER, (1992), 65: 498-502

2. D1 discloses isolated and recombinant nucleic acids encoding human lipocortin (= Annexin) polypeptides, host cells producing such and their medical use. SEQ ID No:20 from D1 is 100% identical to SEQ ID No:1 of the present application.

D2 discloses a method of detecting Annexin I mRNAs by hybridisation to cp35 cDNA.

D3 postulates that phosphorylation of lipocortin I (=Annexin I) is regulating the MDR phenotype. Specifically it is stated that "Thus we hypothesize that phosphorylation of lipocortin I ... may play a role in regulating the expression of the MDR phenotype".

D4 discloses that Annexin II is overexpressed in a multidrug resistant cancer cell line.

3. The present application discloses the cloning of the previously known, MDR implicated protein P-40, through screening of a cDNA library with a monoclonal antibody (IPM96). Upon sequencing, P-40 was shown to be identical to Annexin I. P-40/Annexin I expression is increased in drug resistant cells due to an increase in P-40/Annexin I mRNA. Expression of Annexin II and IV is also increased in MDR cells. P-40/Annexin I thus appears to play a direct role in conferring resistance to anticancer drugs.

4. **Novelty** (Article 33(2) PCT)

- 4.1. Present claims 1-5, 10, 11, 13 and 14 do not satisfy the novelty requirements of the PCT because the subject-matter they relate to, i.e. nucleic acids, vectors and recombinant host cells encoding members of the Annexin family, has already been disclosed in D1. Although D1 does not specify Annexins "for assessing or modulating MDR", such an **indication of an intended use is not limiting the scope of said claims** which are thus found to lack novelty under the terms of Article 33(2) PCT. Claims 13 and 14 are also found to lack novelty in light of D1, since recombinant expression of Annexin and Annexin I in particular, **inherently** confer multidrug resistance to host cells.
- 4.2. Claims 8 and 9, relating to detection of Annexins by hybridisation, are not novel in light of D2 which discloses the same methodology. Again, the fact that the presence of Annexin correlates with Annexin-based MDR is an inherent feature of the claimed subject-matter that cannot be used to reinstate novelty over the prior art.

5. **Inventive step** (Article 33(3) PCT)

- 5.1. It is also noted that D3 and D4 disclose a role -however hypothetical- for Annexin I and II respectively in the MDR phenotype. Annexins were found to be overexpressed in drug resistant cell lines that lacked other genes known to be implicated in MDR (e.g. P-glycoprotein). The IPEA is of the opinion that these disclosures would have prompted the skilled person to investigate the role of

Annexins in MDR with a more than reasonable expectation of success. Claims 1-7 and 15-29 are thus found to lack an inventive step under the terms of Article 33(3) PCT.

- 5.2. Dependent claims 11 and 12 are not considered inventive in light of the prior art and the arguments presented under item 3.1. The construction of recombinant vectors containing any combination of known nucleic acids, belongs to the standard methodology of molecular biology and can be performed without the application of inventive skill as required by Article 33(3) PCT.

**6. Industrial applicability (Article 33(4) PCT)**

The subject-matter of claims 1-19, 24 and 25 appears industrially applicable.

**Re Item VII**

**Certain defects in the international application**

1. Contrary to the requirements of Rule 5.1(ii) PCT, documents D1-D4 are not identified in the description and the relevant background art disclosed therein is not briefly discussed.

**Re Item VIII**

**Certain observations on the international application**

1. It is stated on page 29, line 6 of the application that experiments with Annexins II-XI **will** be carried out to verify the role of Annexins II-XI in MDR. Since such experiments are not disclosed in the application, claims to Annexins other than Annexin I in relation to MDR are unsupported under the terms of Article 6 PCT.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/00992

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 15-17  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

/CA 98/00992

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12Q1/68 C12N15/11 A61K31/70  
 A61K39/395 A61K38/17 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86 04094 A (BIOGEN NV) 17 July 1986 see whole document, example B and sequences in the claims. ---	1-5,7-11
X	HORSEMAN, N.D. ET AL.: "Cell and species distribution of prolactin-inducible annexin I mRNA" GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 85, no. 3, March 1992, pages 405-14, XP002097084	7
A	see abstract; figures 1,3 --- -/--	6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

19 March 1999

Date of mailing of the international search report

07/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WANG, Y. ET AL.: "Overexpression of a 40-kDa protein in human multidrug resistant cells."            BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,            vol. 236, no. 2, 17 July 1997, pages 483-8, XP002097085            cited in the application            see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>BHUSHAN, A. ET AL.: "Increased tyrosinase phosphorylation of lipocortin I in multidrug resistant sarcoma 180 cells."            PROCEEDINGS OF THE 82ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,            vol. 32, no. 0, 15 - 18 May 1991, pages 362-Abstr. 2148, XP002097086            see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>COLE, S.P.C: ET AL.: "Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell."            BRITISH JOURNAL OF CANCER,            vol. 65, no. 4, April 1992, pages 498-502, XP002097087            see abstract            see page 501, left-hand column, paragraph 2 - right-hand column, paragraph 2</p> <p style="text-align: center;">---</p>	
P, X	<p>CAROLLO, M. ET AL.:            "Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin I"            ONCOLOGY RESEARCH,            vol. 10, no. 5, July 1998, pages 245-54, XP002097088            see abstract</p> <p style="text-align: center;">-----</p>	<p>6,7,19, 20</p>

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/CA 98/00992

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8604094 A	17-07-1986	US 4879224 A	07-11-1989
		US 4874743 A	17-10-1989
		AT 108830 T	15-08-1994
		AU 601676 B	20-09-1990
		AU 5318286 A	29-07-1986
		DE 3689977 D	25-08-1994
		DE 3689977 T	27-10-1994
		DK 433686 A	10-09-1986
		EP 0209568 A	28-01-1987
		FI 863626 A	09-09-1986
		JP 7089996 A	04-04-1995
		JP 7087980 A	04-04-1995
		JP 7101994 A	18-04-1995
		JP 7087789 B	27-09-1995
		JP 62501679 T	09-07-1987
		US 5081019 A	14-01-1989
		US 4950646 A	21-08-1990

---



# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 98/00992

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12Q1/68 C12N15/11 A61K31/70  
A61K39/395 A61K38/17 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86 04094 A (BIOGEN NV) 17 July 1986 see whole document, example B and sequences in the claims. ---	1-5,7-11
X	HORSEMAN, N.D. ET AL.: "Cell and species distribution of prolactin-inducible annexin I mRNA" GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 85, no. 3, March 1992, pages 405-14, XP002097084	7
A	see abstract; figures 1,3 --- -/--	6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 March 1999

Date of mailing of the international search report

07/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/CA 98/00992

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WANG, Y. ET AL.: "Overexpression of a 40-kDa protein in human multidrug resistant cells."  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,  vol. 236, no. 2, 17 July 1997, pages 483-8, XP002097085  cited in the application  see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>BHUSHAN, A. ET AL.: "Increased tyrosinase phosphorylation of lipocortin I in multidrug resistant sarcoma 180 cells."  PROCEEDINGS OF THE 82ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,  vol. 32, no. 0, 15 - 18 May 1991, pages 362-Abstr. 2148, XP002097086  see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>COLE, S.P.C. ET AL.: "Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell."  BRITISH JOURNAL OF CANCER,  vol. 65, no. 4, April 1992, pages 498-502, XP002097087  see abstract  see page 501, left-hand column, paragraph 2 - right-hand column, paragraph 2</p> <p style="text-align: center;">---</p>	
P,X	<p>CAROLLO, M. ET AL.:  "Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin I"  ONCOLOGY RESEARCH,  vol. 10, no. 5, July 1998, pages 245-54, XP002097088  see abstract</p> <p style="text-align: center;">-----</p>	6,7,19, 20

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/ 00992

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 15-17  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No

PCT/CA 98/00992

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8604094 A	17-07-1986	US 4879224 A	07-11-1989
		US 4874743 A	17-10-1989
		AT 108830 T	15-08-1994
		AU 601676 B	20-09-1990
		AU 5318286 A	29-07-1986
		DE 3689977 D	25-08-1994
		DE 3689977 T	27-10-1994
		DK 433686 A	10-09-1986
		EP 0209568 A	28-01-1987
		FI 863626 A	09-09-1986
		JP 7089996 A	04-04-1995
		JP 7087980 A	04-04-1995
		JP 7101994 A	18-04-1995
		JP 7087789 B	27-09-1995
		JP 62501679 T	09-07-1987
		US 5081019 A	14-01-1989
		US 4950646 A	21-08-1990

---

Replaced  
Article 31

While the property of a host cell to become MDR is demonstrated with human P-40/Annexin I other Annexins (II-XI), non-human Annexins, other biologically functional genes/cDNA-related to Annexins can also be used in the context of the present invention. For example, Mouse Annexin I  
5 could be used in some embodiments of the present invention as will be recognized by a person of ordinary skill.

Annexins are part of a gene family of multifunctional calcium - and phospholipid - binding protein (for a review see Raynald et al., 1994, Biochem., Biophys. Acta., 1197:45-62). They have been described in many  
10 organisms from mammals, to molds and even plants, and their similar functional properties in  $Ca^{2+}$  and phospholipid are explainable by their common primary structure (Raynald et al., 1994, supra). Indeed, some of the Annexins are thought to have originated from a common ancestor (Raynald et al., 199, supra). Moreover, the family of Annexin genes shows very significant identity between  
15 human, rat, and mouse homologs (Raynald et al., 1994, supra). It will be clear to the person of ordinary skill that the present invention is not to be limited to human Annexins as homologs having the biological function of Annexin-based MDR can be used within the context of the present invention.

Furthermore, since Annexins are found in diverse  
20 evolutionary distant organisms such as plants, yeasts, and parasites (Raynald et al., 1994, supra), the present invention has very broad implications. For example, the present invention opens the way to use Annexins from diverse organisms, such as yeast (i.e. *Candida albicans*) and parasites as therapeutic targets. Antifungal drugs, for example, could be identified by using yeast  
25 Annexins as therapeutic targets.

The presence of Annexins in plants could find utility in the development of specific crop resistance, by for example, increasing the expression level of at least one Annexin.

In accordance with yet another aspect of the present  
30 invention, there is provided a method of reducing Annexin-based MDR in a cell

Replaced  
by  
Article 34

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule encoding an Annexin family member, a member of the multidrug resistance (MDR) gene family for assessing or modulating MDR in a cell.

5

2. The isolated nucleic acid molecule of claim 1, wherein said cell is selected from an animal cell, mammalian cell, a human cell, a parasitic cell and a fungal cell.

10

3. The isolated nucleic acid molecule of claim 1, comprising a nucleic acid sequence which is at least 90% identical to a sequence selected from the group consisting of a nucleotide sequence encoding an Annexin polypeptide selected from Annexin I to Annexin XI, or a nucleotide sequence complementary thereto.

15

4. The isolated nucleic acid molecule of claim 1, 2 or 3, wherein said Annexin is Annexin I and said Annexin polypeptide is the Annexin I polypeptide which comprises the complete amino acid sequence set forth in Figure 1C.

20

5. The isolated nucleic acid molecule of claim 1 or 2, wherein said Annexin is Annexin I and said nucleotide sequence comprises the nucleotide sequence as set forth in Figure 1B.

25

6. A method of detecting and/or assessing Annexin-based MDR in a sample comprising:

a) contacting said sample with an isolated nucleic acid molecule consisting of 10 to 50 nucleotides specifically hybridizing to RNA and/or DNA encoding an Annexin, wherein said nucleic acid molecule is or is complementary to a nucleotide sequence consisting of at least 10 consecutive  
5 nucleotides from the nucleic acid sequence of one of Annexin I to XI, under hybridization conditions; and

b) detecting the presence of said molecule bound to Annexin nucleic acid.

10 7. A kit for detecting and/or quantifying an Annexin nucleic acid in a sample comprising at least one container means having disposed therein an isolated nucleic acid molecule consisting of 10 to 50 nucleotides specifically hybridizing to RNA and/or DNA encoding an Annexin, wherein said  
15 nucleic acid molecule is or is complementary to a nucleotide sequence consisting of at least 10 consecutive nucleotides from the nucleic acid sequence of one of Annexin I to XI.

8. A recombinant vector for modulating and/or inhibiting and/or increasing Annexin-based MDR in a cell comprising the isolated nucleic  
20 acid molecule of claim 1 operably linked to a promoter element.

9. The recombinant vector of claim 8, wherein Annexin is Annexin I.

25 10. The recombinant vector of claim 9, being pCDNA3/P-40 or pC1N4P-40.

11. A cell that contains the recombinant vector of claim 8 or  
9.

12. A method of identifying compounds that affect  
5 Annexin-based MDR, said method comprising:

- a) incubating the cell of claim 11 in the presence of a  
potential Annexin-based MDR-affecting compound in the presence and absence  
of a drug; and
- b) assessing the effect of said compound on the resistance  
10 to said drug.

13. The method of claim 12, wherein said compound is  
selected from the group consisting of a nucleic acid molecule, a dominant  
negative mutant of an Annexin, a mutant Annexin, an antibody to Annexin, a  
15 peptide, and a small molecule.

14. The method of claim 13, wherein said compound is an  
Annexin I antisense molecule.

20 15. A method of reducing Annexin-based MDR in a cell  
comprising: administering thereto a therapeutically effective amount of a  
compound selected from the group consisting of a nucleic acid molecule, a  
dominant negative mutant of an Annexin, a mutant Annexin, an antibody to  
Annexin, a peptide, and a small molecule.

25

16. The method of claim 15, wherein said compound is an  
Annexin I antisense molecule.



17. The method of claim 15, wherein said compound is a calcium chelator or a calcium channel blocker.

5 18. A pharmaceutical composition for reducing MDR in a cell comprising an Annexin-based MDR affecting compound together with a suitable pharmaceutically acceptable carrier.

19. A method of diagnosing the presence or predisposition of Annexin-based MDR in a patient comprising:  
10 a) taking a sample from said patient;  
b) determining the amount of Annexin protein and/or RNA in said sample;  
c) diagnosing the presence or predisposition of Annexin-based MDR in said patient, wherein an increased amount of said  
15 Annexin protein and/or RNA in said sample as compared to a control sample indicates the presence or predisposition towards Annexin-based MDR.


20. A method of diagnosing the presence or predisposition of Annexin-based MDR in a pathogen comprising:  
20 a) taking a sample from said pathogen;  
b) determining the amount of Annexin protein and/or RNA in said sample;  
c) diagnosing the presence or predisposition of Annexin-based MDR in said pathogen, wherein an increased amount of said  
25 Annexin protein and/or RNA in said sample as compared to a control sample indicates the presence or predisposition towards Annexin-based MDR.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/47, C12Q 1/68,</b> <b>C12N 15/11, A61K 31/70, 39/395, 38/17,</b> <b>G01N 33/50</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/21980</b>  <b>(43) International Publication Date:</b> 6 May 1999 (06.05.99)
<b>(21) International Application Number:</b> PCT/CA98/00992  <b>(22) International Filing Date:</b> 26 October 1998 (26.10.98)  <b>(30) Priority Data:</b> 2,219,299                      24 October 1997 (24.10.97)                      CA  <b>(71) Applicant (for all designated States except US):</b> MCGILL UNIVERSITY [CA/CA]; 3550 University Street, Montreal, Quebec H3A 2A7 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GEORGES, Elias [CA/CA]; 2095, rue de Vouvray, Chomedey, Laval, Quebec H7M 3J7 (CA). WANG, Ying [CA/CA]; 21566 Lakeshore, Ste-Anne-de-Bellevue, Quebec H9X 1S2 (CA).  <b>(74) Agents:</b> DUBUC, Jean, H. et al.; Goudreau Gage Dubuc & Martineau Walker, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

**(54) Title:** P-40/ANNEXIN I AND RELATED PROTEINS AND THEIR ROLE IN MULTIDRUG RESISTANCE

**(57) Abstract**

The present invention relates in general to multidrug resistance (MDR) in cells. In particular, the present invention relates to the identification of a new member of the MDR gene family, P-40, as well as to the identification of P-40 related genes (homologs) as being additional members of the MDR gene family. The present invention therefore relates to nucleic acid molecules encoding P-40 protein and P-40 protein homologs, to multidrug resistant cells containing these nucleic acid molecules; to hybridomas containing antibodies to P-40 and P-40 homologs; to nucleic acid probes for the detection of these nucleic acid molecules; to a method of detection of such nucleic acid molecules or of the P-40 protein or P-40 homologs, to bioassays comprising the nucleic acid molecules encoding P-40 or P-40 homologs, P-40 protein or P-40 protein homologs, or antibodies of the present invention to diagnose, assess or prognose MDR in an animal; to therapeutic uses of the nucleic acid molecules of the present invention (i.e. antisense), protein or antibodies of the present invention; and to methods of preventing MDR in an animal.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TITLE OF THE INVENTION**

P-40/ANNEXIN I AND RELATED PROTEINS AND THEIR ROLE I MULTIDRUG RESISTANCE

**5 FIELD OF THE INVENTION**

The present invention relates in general to multidrug resistance (MDR) in cells. In particular, the present invention relates to the identification of a new member of the MDR gene family, P-40, as well as to the identification of P-40 related genes (homologs) as being further members of the

10 MDR gene family. The present invention therefore relates to nucleic acid molecules encoding P-40 protein and P-40 proteins homologs, to multidrug resistant cells containing these nucleic acid molecules; to hybridomas containing antibodies to P-40 and P-40 homologs; to nucleic acid probes for the detection of these nucleic acid molecules; to a method of detection of such nucleic acid

15 molecules or of the P-40 protein or P-40 homologs; to bioassays comprising the nucleic acid molecules encoding P-40 or P-40 homologs, P-40 protein or P-40 protein homologs, or antibodies of the present invention to diagnose, assess or prognose MDR in an animal; to therapeutic uses of the nucleic acid molecules of the present invention (i.e. antisense), protein or antibodies of the present

20 invention; and to methods of preventing MDR in an animal.

**BACKGROUND OF THE INVENTION**

The ability of malignant cells to develop resistance to multiple anticancer drugs is a major obstacle in the treatment of cancers (Ferguson et

25 al., 1989, Cancer Bulletin 41(1): 7-13). Studies using *in vitro* model systems have led to the identification of several proteins which confer resistance to different classes of anticancer drugs (Pastan et al., 1987, New England J. Med. 316(22): 1388-1393; Bradley et al., 1988, Biochim. Biophys. Acta 948: 87-128). The overexpression of P-glycoprotein (P-gp) and the multidrug

resistance associated protein (MRP) in cells selected with hydrophobic cytotoxic drugs (*Vinca alkaloids*, anthracyclines and epipodophyllotoxins) have been shown to confer a multidrug resistance phenotype (Gottesman et al., 1993, Ann. Rev. Biochem. 62: 385-427; Endicott et al., 1989, Ann. Rev. of Biochem. 58: 137-171; Cole et al., 1996, Cancer Treat. Res. 87: 39-62). Both P-gp and MRP belong to a large family of ATP trafficking proteins that are evolutionary conserved and mediate the transport of numerous ligand ranging from ions to large polypeptides (Higgins et al., 1992, Ann. Rev. Cell Biol. 8: 67-113). In tumor cell lines, P-gp and MRP reduce the accumulation of drugs via an energy dependent drug efflux mechanism (Shapiro et al., 1994, J. Biol. Chem. 269(5): 3745-3754; Doige et al., 1992, Biochim. Biophys. Acta 1109: 161-171).

P-gp and MRP expression has been detected in normal tissues and is thought to mediate the transport of normal cell metabolites and xenobiotics (Cordon-Cardo et al., 1990, J. Histochem. Cytochem. 38(9): 1277-1287; Bradley et al., 1990, J. Cell. Physiol. 145: 398-408; Thorgeirsson et al., 1987, Science 236: 1120-1122; Thiebaut et al., 1987, Proc. Nat. Acad. Sc. USA 84: 7735-7738). Consistent with these speculations, inactivation of both alleles of P-gp from the mouse genome has led to the accumulation of drugs and natural products in many organs where P-gp is highly expressed (Schinkel et al., 1997, Proc. Nat. Acad. Sc. 94(8): 4028-4033; Schinkel et al., 1994, Cell 77: 491-502). High levels of P-gp has been shown in 20 - 70% of tumors from different cancers (Tishler et al., 1992, J. Neurosurgery 76: 507-512; Abe et al., 1994, Japan J. Cancer Res. 85(5): 536-541; Baker et al., 1989, ? : 87-97; Belloni et al., 1989, Cancer and Metastasis Rev. 8: 353-389; Charpin et al., 1994, J. Nat. Cancer Inst. 86(20): 1539-1545; Fojo et al., 1987, Proc. Nat. Acad. Sc. 84: 265-269; Henson et al., 1992, J. Neuro-Oncology 14: 37-43; Hijazi et al., 1994, Am. J. Clin. Pathol. 102(1): 61-67; Mattern et al., 1994,

Anticancer Res. 14(2A): 417-419), and in some tumors (e.g. haemopoietic tumors and childhood malignancies) P-gp expression has been shown to predict clinical drug resistance and long term survival (Nooter et al., 1994, Leukemia Research 18(4): 233-243; Chan et al., 1995, Hematology - Oncology Clinics of North America 9(2): 275-318; Chan et al., 1991, New Engl. J. Med., 325:1608-1614). However, the lack of P-gp expression in other multidrug resistant tumors indicates other cellular changes that confer resistance to anticancer drugs (Lee et al., 1997, J. Cell. Biochem. 65(4): 513-526; Baggetto, Bull. Cancer. 84(4): 385-390; Linn et al., 1994, J. Clin. Oncol. 12(4): 812-819; Lonn et al., 1994, Intern. J. Cancer 58(1): 40-45; Sognier et al., 1994, Biochem. Pharmacol. 48( 2): 391-401). Some of the cellular changes identified in drug resistant cells include the overexpression of MRP (Zaman et al., 1994, Proc. Nat'l Acad. Sc. USA 91(19): 8822-8826), alterations in glutathione-S-transferase activity or GSH levels (Tew, 1994, Cancer Res. 54(15): 4313-4320), reduction in topoisomerase II levels or activity (Frelich et al., 1995, J. Biol. Chem. 270(15): 21429-21432), overexpression of LRP (the Lung Resistance Protein, a the component of human vaults) (Scheffer et al., 1995, Nature Med. 1(16): 578-578) and alteration in functions or levels of proteins mediating apoptosis or programmed cell death (Lowe et al., 1993, Cell 74(6): 957-967; Lowe et al., 1994, Science 266(5186): 807-810).

There thus remains a need to identify other cellular changes that confer drug resistance.

The overexpression of a 40 kDa protein (P-40) alone or together with P-gp or MRP in MDR cell lines (Wang et al., 1997, Biochem. Biophys. Research Communications. 236(2): 483-488) has been previously reported. However, further studies were required to demonstrate a direct role for P-40, if any, in drug metabolism and multidrug resistance (MDR). Indeed, it was disclosed that it was unknown and unclear whether P-40 could modulate a MDR phenotype directly or indirectly (Wang et al., 1997, *supra* ).

There thus remains a need to determine whether P-40 is indeed directly implicated in MDR. In the affirmative, there also remains a need to identify the molecular determinant of this MDR, in the form of a nucleic acid and for protein in order to open the way for the obtention of diagnostic, therapeutic and research tools in the field of multidrug resistance.

The present invention seeks to meet these and other needs.

#### **SUMMARY OF THE INVENTION**

The invention concerns the demonstration that P-40 has a direct role in multidrug resistance.

Further, the invention relates to the identification of P-40 as a member of the MDR gene family and to the identification of P-40/Annexin I related genes as members of this broadened MDR gene family.

In addition, the invention relates to the identification of Annexin II and IV as potential MDR determinants. Thus, the invention relates to the identifications of Annexins (I to XI, also referred thereto herein P-40 and P-40 homologs) as potential members of the MDR gene family. Broadly therefore, the present invention also relates to the identification of Annexin-based MDR in cells.

The present invention further relates to the isolated nucleic acid molecules encoding P-40 or fragment thereof and to the identification of P-40 as Annexin I.

The invention in addition relates to purified P-40 polypeptides, homologs thereof, or epitope binding portions thereof and the use thereof in multidrug resistance. The invention also provides a specific detection method for P-40 nucleic acids encoding P-40 proteins or homologs thereof, polypeptides or fragments thereof in a sample.

In addition, the invention provides a recombinant nucleic acid molecule comprising P-40 (or homologs thereof) operationally linked to a

promoter, efficient in initiating transcription thereof in a host cell as well as to such a host cell.

As well, the invention provides a non-human organism containing the nucleic acid molecule mentioned above. Further, the invention provides an antisense P-40 or P-40-related (Annexin I-related) nucleic acid molecule.

The invention further provides an antibody having specific binding affinity towards P-40, P-40 homologs or an epitope-containing-region thereof. In one embodiment, the antibody is a monoclonal. The invention also provides the hybridoma producing the monoclonal antibody.

The invention also seeks to provide a method for the detection of P-40 or P-40 protein homologs or portions thereof in a sample. In one embodiment, such a method is quantitative.

Furthermore, the invention seeks to provide a diagnostic kit comprising a first contained means containing the above-mentioned antibody, and second container means containing a conjugate comprising a binding partner of the monoclonal antibody and a label.

The invention seeks to provide diagnostic methods for human disease and particularly for cancer and the multidrug resistance of cancer cells. Preferably, a method for evaluating the predisposition of a cancer tumor to be and/or become multidrug resistance is provided herein.

The invention further seeks to provide therapeutic methods involving the P-40 nucleic acid homologs, variants or parts thereof, antisense thereof, P-40 protein, P-40 protein homologs or P-40 antibodies.

The present invention also relates to a kit comprising the oligonucleotide primers or agents or ligands of the present invention which are specific to annexins and more particularly to annexin I.

For example, a compartmentalized kit in accordance with the present invention includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers



or strips of plastic or paper. Such containers allow the efficient transfer of reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample (DNA or cells), a container which contains the primers used in the assay (or antibodies or other ligands), containers which contain enzymes, containers which contain wash reagents, and containers which contain the reagents used to detect the extension products (or reagents to detect the antibodies or ligands).

It shall be understood that in certain situations it might be beneficial to render a cell MDR by providing therein at least one nucleic acid encoding an Annexin (or at least one Annexin protein) so as to give this cell a growing advantage with respect to wild-type cells in certain growth conditions (i.e. presence of drug).

It is shown herein that P-40 is Annexin I. Annexin I is a member of a large family of  $\text{Ca}^{2+}$  phospholipid binding proteins [for review see (Raynal et al., 1994, *Biochim. Biophys. Acta.* 1197: 63-93), implicated in several cellular mechanisms including intracellular membrane vascular trafficking and exocytosis process (Creutz, 1992, *Science.* 258: 924-93; Lin et al., 1992, *Cell* 70: 283-291; Creutz et al., 1992, *J. Cell Science.* 103: 1177-1192). However, Annexin I has not been previously implicated in drug resistance or suggested to be implicated hereinto. The inventors are then the first to show the role of Annexin I in expression of drug resistance to anticancer drugs. Thus, the present invention is the first to show an Annexin-based multidrug resistance pathway in cells.

Nucleotide sequences are presented herein by single strand, in the 5' to 3' direction, from left to right, using the one letter nucleotide symbols

as commonly used in the art and in accordance with the recommendations of the IUPAC-IUB Biochemical Nomenclature Commission.

The present description refers to a number of routinely used recombinant DNA (rDNA) technology terms. Nevertheless, definitions of selected examples of such rDNA terms are provided for clarity and consistency.

As used herein, "isolated nucleic acid molecule", refers to a polymer of nucleotides. Non-limiting examples thereof include DNA and RNA molecules purified from their natural environment.

The term "recombinant DNA" as known in the art refers to a DNA molecule resulting from the joining of DNA segments. This is often referred to as genetic engineering.

The term "DNA segment", is used herein, to refer to a DNA molecule comprising a linear stretch or sequence of nucleotides. This sequence when read in accordance with the genetic code, can encode a linear stretch or sequence of amino acids which can be referred to as a polypeptide, protein, protein fragment and the like.

The terminology "amplification pair" refers herein to a pair of oligonucleotides (oligos) of the present invention, which are selected to be used together in amplifying a selected nucleic acid sequence by one of a number of types of amplification processes, preferably a polymerase chain reaction. Other types of amplification processes include ligase chain reaction, strand displacement amplification, or nucleic acid sequence-based amplification, as explained in greater detail below. As commonly known in the art, the oligos are designed to bind to a complementary sequence under selected conditions.

The nucleic acid (i.e. DNA or RNA) for practising the present invention may be obtained according to well known methods.

Oligonucleotide probes or primers of the present invention may be of any suitable length, depending on the particular assay format and the particular needs and targeted genomes employed. In general, the oligonucleotide probes or primers are at least 12 nucleotides in length,

preferably between 15 and 24 molecules, and they may be adapted to be especially suited to a chosen nucleic acid amplification system. As commonly known in the art, the oligonucleotide probes and primers can be designed by taking into consideration the melting point of hybridization thereof with its targeted sequence (see below and in Sambrook et al., 1989, Molecular Cloning - A Laboratory Manual, 2nd Edition, CSH Laboratories; Ausubel et al., 1989, in Current Protocols in Molecular Biology, John Wiley & Sons Inc., N.Y.).

"Nucleic acid hybridization" refers generally to the hybridization of two single-stranded nucleic acid molecules having complementary base sequences, which under appropriate conditions will form a thermodynamically favored double-stranded structure. Examples of hybridization conditions can be found in the two laboratory manuals referred above (Sambrook et al., 1989, and Ausubel et al., 1989) and are commonly known in the art. In the case of a hybridization to a nitrocellulose filter, as for example in the well known Southern blotting procedure, a nitrocellulose filter can be incubated overnight at 65°C with a labeled probe in a solution containing 50% formamide, high salt ( 5 x SSC or 5 x SSPE), 5 x Denhardt's solution, 1% SDS, and 100 µg/ml denatured carrier DNA ( i.e. salmon sperm DNA). The non-specifically binding probe can then be washed off the filter by several washes in 0.2 x SSC/0.1% SDS at a temperature which is selected in view of the desired stringency: room temperature (low stringency), 42°C (moderate stringency) or 65°C (high stringency). The selected temperature is based on the melting temperature ( $T_m$ ) of the DNA hybrid. Of course, RNA-DNA hybrids can also be formed and detected. In such cases, the conditions of hybridization and washing can be adapted according to well known methods by the person of ordinary skill. Stringent conditions will be preferably used (Sambrook et al., 1989, supra).

Probes of the invention can be utilized with naturally occurring sugar-phosphate backbones as well as modified backbones including phosphorothioates, dithionates, alkyl phosphonates and  $\alpha$ -nucleotides and the

like. Modified sugar-phosphate backbones are generally taught by Miller, 1988, Ann. Reports Med. Chem. 23:295 and Moran et al., 1987, Nucleic acid molecule. Acids Res., 14:5019. Probes of the invention can be constructed of either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), and preferably of DNA.

5                   The types of detection methods in which probes can be used include Southern blots (DNA detection), dot or slot blots (DNA, RNA), and Northern blots (RNA detection). Although less prepared, labeled proteins could also be used to detect a particular nucleic acid sequence to which it binds. Other detection methods include kits containing probes on a dipstick setup and the  
10                   like.

                  Although the present invention is not specifically dependent on the use of a label for the detection of a particular nucleic acid sequence, such a label might be beneficial, by increasing the sensitivity of the detection. Furthermore, it enables automation. Probes can be labeled according to  
15                   numerous well known methods (Sambrook et al., 1989, supra). Non-limiting examples of labels include  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ . Non-limiting examples of detectable markers include ligands, fluorophores, chemiluminescent agents, enzymes, and antibodies. Other detectable markers for use with probes, which can enable an increase in sensitivity of the method of the invention, include  
20                   biotin and radionucleotides. It will become evident to the person of ordinary skill that the choice of a particular label dictates the manner in which it is bound to the probe.

                  As commonly known, radioactive nucleotides can be incorporated into probes of the invention by several methods. Non-limiting  
25                   examples thereof include kinasing the 5' ends of the probes using gamma  $^{32}\text{P}$  ATP and polynucleotide kinase, using the Klenow fragment of Pol I of *E. coli* in the presence of radioactive dNTP (i.e. uniformly labeled DNA probe using random oligonucleotide primers in low-melt gels), using the SP6/T7 system to transcribe a DNA segment in the presence of one or more radioactive NTP, and  
30                   the like.

As used herein, "oligonucleotides" or "oligos" define a molecule having two or more nucleotides (ribo or deoxyribonucleotides). The size of the oligo will be dictated by the particular situation and ultimately on the particular use thereof and adapted accordingly by the person of ordinary skill.

5 An oligonucleotide can be synthesised chemically or derived by cloning according to well known methods.

As used herein, a "primer" defines an oligonucleotide which is capable of annealing to a target sequence, thereby creating a double stranded region which can serve as an initiation point for DNA synthesis under suitable  
10 conditions.

Amplification of a selected, or target, nucleic acid sequence may be carried out by a number of suitable methods. See generally Kwoh et al., 1990, Am. Biotechnol. Lab. 8:14-25. Numerous amplification techniques have been described and can be readily adapted to suit particular needs of a person  
15 of ordinary skill. Non-limiting examples of amplification techniques include polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-based amplification, the QB replicase system and NASBA (Kwoh et al., 1989, Proc. Natl. Acad. Sci. USA 86, 1173-1177; Lizardi et al., 1988, Biotechnology 6:1197-1202; Malek et al., 1994,  
20 Methods Mol. Biol., 28:253-260; and Sambrook et al., 1989, supra). Preferably, amplification will be carried out using PCR.

Polymerase chain reaction (PCR) is carried out in accordance with known techniques. See, e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159, and 4,965,163 (the disclosures of all three U.S. Patent are  
25 incorporated herein by reference). In general, PCR involves, a treatment of a nucleic acid sample (e.g., in the presence of a heat stable DNA polymerase) under hybridizing conditions, with one oligonucleotide primer for each strand of the specific sequence to be detected. An extension product of each primer which is synthesized is complementary to each of the two nucleic acid strands, with the  
30 primers sufficiently complementary to each strand of the specific sequence to

hybridize therewith. The extension product synthesized from each primer can also serve as a template for further synthesis of extension products using the same primers. Following a sufficient number of rounds of synthesis of extension products, the sample is analysed to assess whether the sequence or sequences  
5 to be detected are present. Detection of the amplified sequence may be carried out by visualization following EtBr staining of the DNA following gel electrophores, or using a detectable label in accordance with known techniques, and the like. For a review on PCR techniques (see PCR Protocols, A Guide to Methods and Amplifications, Michael et al. Eds, Acad. Press, 1990).

10                   Ligase chain reaction (LCR) is carried out in accordance with known techniques (Weiss, 1991, Science 254:1292). Adaptation of the protocol to meet the desired needs can be carried out by a person of ordinary skill. Strand displacement amplification (SDA) is also carried out in accordance with known techniques or adaptations thereof to meet the particular needs (Walker  
15 et al., 1992, Proc. Natl. Acad. Sci. USA 89:392-396; and *ibid.*, 1992, Nucleic Acids Res. 20:1691-1696.

As used herein, the term "gene" is well known in the art and relates to a nucleic acid sequence defining a single protein or polypeptide. A "structural gene" defines a DNA sequence which is transcribed into RNA and  
20 translated into a protein having a specific amino acid sequence thereby giving rise the a specific polypeptide or protein. It will readily recognized by the person of ordinary skill, that the nucleic acid sequence of the present invention can be incorporated into anyone of numerous established kit formats which are well known in the art.

25                   The term "vector" is commonly known in the art and defines a plasmid DNA, phage DNA, viral DNA and the like, which can serve as a DNA vehicle into which DNA of the present invention can be cloned. Numerous types of vectors exist and are well known in the art.

The term "expression" defines the process by which a structural gene is transcribed into mRNA (transcription), the mRNA is then being translated (translation) into one polypeptide (or protein) or more.

5 The terminology "expression vector" defines a vector or vehicle as described above but designed to enable the expression of an inserted sequence following transformation into a host. The cloned gene (inserted sequence) is usually placed under the control of control element sequences such as promoter sequences. The placing of a cloned gene under such control sequences is often referred to as being operably linked to control elements or  
10 sequences.

Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host or both (shuttle vectors) and can additionally contain transcriptional elements such as enhancer elements, termination sequences,  
15 tissue-specificity elements, and/or translational initiation and termination sites.

As used herein, the designation "functional derivative" denotes, in the context of a functional derivative of a sequence whether an nucleic acid or amino acid sequence, a molecule that retains a biological activity (either function or structural) that is substantially similar to that of the original  
20 sequence. This functional derivative or equivalent may be a natural derivatives or may be prepared synthetically. Such derivatives include amino acid sequences having substitutions, deletions, or additions of one or more amino acids, provided that the biological activity of the protein is conserved. The same applies to derivatives of nucleic acid sequences which can have substitutions,  
25 deletions, or additions of one or more nucleotides, provided that the biological activity of the sequence is generally maintained. When relating to a protein sequence, the substituting amino acid as chemico-physical properties which are similar to that of the substituted amino acid. The similar chemico-physical properties include, similarities in charge, bulkiness, hydrophobicity,  
30 hydrophylicity and the like. The term "functional derivatives" is intended to

include "fragments", "segments", "variants", "analogs" or "chemical derivatives" of the subject matter of the present invention.

Thus, the term "variant" refers herein to a protein or nucleic acid molecule which is substantially similar in structure and biological activity to the protein or nucleic acid of the present invention.

The functional derivatives of the present invention can be synthesized chemically or produced through recombinant DNA technology. all these methods are well known in the art.

As used herein, "chemical derivatives" is meant to cover additional chemical moieties not normally part of the subject matter of the invention. Such moieties could affect the physico-chemical characteristic of the derivative (i.e. solubility, absorption, half life and the like, decrease of toxicity). Such moieties are exemplified in Remington's Pharmaceutical Sciences (1980). Methods of coupling these chemical-physical moieties to a polypeptide are well known in the art.

The term "allele" defines an alternative form of a gene which occupies a given locus on a chromosome.

As commonly known, a "mutation" is a detectable change in the genetic material which can be transmitted to a daughter cell. As well known, a mutation can be, for example, a detectable change in one or more deoxyribonucleotide. For example, nucleotides can be added, deleted, substituted for, inverted, or transposed to a new position. Spontaneous mutations and experimentally induced mutations exist. The result of a mutations of nucleic acid molecule is a mutant nucleic acid molecule. A mutant polypeptide can be encoded from this mutant nucleic acid molecule.

As used herein, the term "purified" refers to a molecule having been separated from a cellular component. Thus, for example, a "purified protein" has been purified to a level not found in nature. A "substantially pure" molecule is a molecule that is lacking in all other cellular components.



While the property of a host cell to become MDR is demonstrated with human P-40/Annexin I other Annexins (II-XI), non-human Annexins, other biologically functional genes/cDNA-related to Annexins can also be used in the context of the present invention. For example, Mouse Annexin I  
5 could be used in some embodiments of the present invention as will be recognized by a person of ordinary skill.

Annexins are part of a gene family of multifunctional calcium - and phospholipid - binding protein (for a review see Raynald et al., 1994, Biochem., Biophys. Acta., 1197:45-62). They have been described in many  
10 organisms from mammals, to molds and even plants, and their similar functional properties in  $\text{Ca}^{2+}$  and phospholipid are explainable by their common primary structure (Raynald et al., 1994, supra). Indeed, some of the Annexins are thought to have originated from a common ancestor (Raynald et al., 199, supra). Moreover, the family of Annexin genes shows very significant identity between  
15 human, rat, and mouse homologs (Raynald et al., 1994, supra). It will be clear to the person of ordinary skill that the present invention is not to be limited to human Annexins as homologs having the biological function of Annexin-based MDR can be used within the context of the present invention.

Furthermore, since Annexins are found in diverse  
20 evolutionary distant organisms such as plants, yeasts, and parasites (Raynald et al., 1994, supra), the present invention has very broad implications. For example, the present invention opens the way to use Annexins from diverse organisms, such as yeast (i.e. *Candida albicans*) and parasites as therapeutic targets. Antifungal drugs, for example, could be identified by using yeast  
25 Annexins as therapeutic targets.

The presence of Annexins in plants could find utility in the development of specific crop resistance, by for example, increasing the expression level of at least one Annexin.

In accordance with yet another aspect of the present  
30 invention, there is provided a method of reducing Annexin-based MDR in a cell

or animal, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition according to the instant invention.

For pharmaceutical administration, the said polypeptide may be incorporated into preparations in either liquid or solid forms using carriers and excipients conventionally employed in the pharmaceutical art, optionally in combination with further active ingredients. The preparation may, for example, be applied orally, parenterally, enterally or preferably topically. Preferred forms include, for example, solutions, emulsions, gels, sprays, lotions, ointments, creams or powders.

One of ordinary skill can readily determine the amounts of Annexin-based MDR reducing agent to be administered. It is apparent that the dosage will be dependent on the particular treatment used. It should also be clear that the dosage should be chosen to display the biological activity without causing adverse effects. It will be understood that age, sex, type of disease, of formulation and other variables known to the person of ordinary skill will affect determination of the dosage to be used.

The pharmaceutically acceptable carriers and excipients are well known in the art. A representative textbook thereon is Remington's Pharmaceutical Sciences, 1980, 16th Ed., Mack Eds.

Advantageously the compositions may be formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredient. The total daily dose may, of course, be varied depending on the subject treated and the particular use of the composition. This can obviously be adapted by the treating professional.

In general, techniques for preparing antibodies (including monoclonal metabolism and hybridomas) and for detecting antigens using antibodies are well known in the art (Campbell, 1984, In "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", Elsevier Science Publisher, Amsterdam, The Netherlands) and in Harlow et al., 1988 (in: Antibody - A Laboratory Manual, CSH Laboratories).

The present invention opens the way to the identification of agonists and antagonists of Annexins with respect to their role in MDR. An assay for Annexin-based MDR activity in cells can be used to assess the effect of agents on Annexins function in drug resistance and therefore identify such agonists or antagonists. Non-limiting examples of such agents include nucleic acid molecules, peptides, antibodies, carbohydrates, or other pharmaceutical agents.

The present invention also provides polyclonal, monoclonal antibodies, or humanized versions thereof, chimeric antibodies and the like which inhibit or neutralize their respective Annexin targetted antigens *in vivo* and/or specific thereto.

Treatments comprise parenteral administration of multiple or single doses of the above listed antibodies and derivatives thereof. The dosage will be varied by the practicing professional depending on the usual parameters such as pharmacodynamic characteristics the route of administration, recipient's characteristics, symptoms and/or disease thereof and the like. A daily dosage of active ingredient can be for example about 0.1 to 100 mg/kg of body weight, ordinarily 0.5 - 50 and preferably 1-10 mg/kg per day, i.e. divided doses ranging from 1-6 times per day or alternatively in sustained release form.

The non-human animals of the present invention having a transgenic interruption or alteration of the Annexin endogenous gene(s) (knock-out animal) and/or into the genome in which transgenes directing expression of Annexin(s) has been introduced include vertebrates such as rodents, non-human primates, amphibians, reptiles and the like. These animals are prepared in accordance with known methods. The same applies to transgenic plants.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Having thus generally described the invention, reference will now be made to the accompanying drawings, showing by way of illustration a preferred embodiment thereof, and in which:

5                   Figure 1A shows a restriction map of the gene encoding P-40. The map for the 1.4 kb fragment isolated from  $\lambda$ gt11 expression library with IPM96 monoclonal antibody. The restriction enzyme sites are indicated by the arrows. The solid bar indicates the coding sequence for P-40 or Annexin I. The thin lines to the left and right of the solid bar indicate the 5' and 3' non-coding regions. Figure 1B shows the nucleic acid sequence of P-40/Annexin I. Figure 1C shows the amino acid sequence of P-40/Annexin I. Figure 1D shows the nucleic acid sequence of both strands of P-40/Annexin I and hence shows examples of antisense nucleic acid molecules which can be used in accordance with the present invention.

15                   Figure 2 shows the *in vitro* expression of P-40. The *in vitro* expression of P-40 gene was performed using the T7 promoter directed transcription in TA PCRII cloning vector. Figure 2a shows *in vitro* transcribed and translated mixes containing PCRII vector only immunoprecipitated with IPM96 mAb or PCRII plus 1.4 kb insert immunoprecipitated with IPM96 mAb or an irrelevant IgG2b (lanes 2 and 3, respectively). Lanes 1-4 of figure 2b show the same samples as in lanes 1 and 2 of Fig. 2a but transferred to nitrocellulose membrane and probed with a specific antibody to P-40 (IPM96 mAb ; Wang et al., 1997, Biochem. Biophys. Res. Com. 236(2): 483-488) or an irrelevant IgG2b, respectively.

25                   Figure 3 shows the analysis of protein and mRNA levels in drug sensitive and resistant cells. In Fig. 3a, total cell extract from drug sensitive (MCF-7, SKOV3 and H69) and drug resistant human MDR cell lines (MCF-/Adr, SKOV/VLB<sup>1.0</sup> and H69/AR) were fractionated on SDS-PAGE and transferred to nitrocellulose membrane. The membrane was probed with IPM96 monoclonal antibody. P-40 (or annexin I) is seen in extracts from drug resistant

30

level of P-40 is detected in SKOV3 drug sensitive cells but not in MCF-7 or H69 cells. For mRNA levels in the same cell lines, total RNAs were resolved on agarose gel and transferred to nylon membrane and probed with <sup>32</sup>P-dATP labelled 1.4 kb fragment encoding for P-40 (or annexin I) and actin (Fig. 3b).

5 Figure 3b shows that the expression of a 1.6 kb mRNA in drug sensitive and resistant MDR cells correlates with levels of P-40 (or annexin I) in the same cell lines.

Figure 4 shows the post-translational modification of P-40 or Annexin I in MCF-7/AR cells. Cells were metabolically labeled with <sup>35</sup>S-methionine or <sup>32</sup>P inorganic phosphate and radiolabeled protein were immunoprecipitated  
10 with an irrelevant IgG2b or IPM96 mAb (lanes 1 and 3 or 2 and 4, respectively).

Figure 5 shows the expression of Annexins I, II, IV and VI in drug sensitive and resistant cells. Total cell lysates from drug sensitive (MCF-7, H69, SKOV3 and AuxB1) and resistant (MCF-7/Adr, H69/AR, SKOV3/VLB<sup>1,0</sup>,  
15 SKOV3/VLB0.06 and CHC5) or revertant (H69/PR) were resolved on SDS-PAGE and transferred to nitrocellulose membrane. The nitrocellulose membranes was then probed with anti-Annexin I, II, IV or VI monoclonal antibodies.

Figure 6 shows the drug sensitivity assays for P-40 transient  
20 transfectants. The level of P-40 (Annexin I) expression in MCF-7 transiently transfected cells was determined by Western blotting (figure 6a). MCF-7 cells transfected with pCDNA3 vector without or with P-40 (Annexin I) gene were incubated in the absence and presence of increasing concentrations of Taxol (figure 6b) or adriamycin (doxorubicin) (figure 6c).

25 Figure 7 shows the P-40 (or annexin I) construct pCIN4-P-40. The full length P-40 (or annexin I) cDNA was cloned into the Not-1 site of eukaryotic expression vector pCIN4 in both sense and antisense orientations. This places (or operately links to the promoter) the P-40 (or annexin I) adjacent to the viral CMV promoter, which directs its expression. The neomycin  
30 phosphotransferase gene is also present on the construct with its expression

being driven by the same promoter element located ahead of multi-cloning sites (indicated in the map), thus providing G418 resistance to cells containing a construct. To facilitate translation of a second open reading frame (neomycin phosphotransferase), the encyphalomyocarditis virus internal ribosome entry sites (IRES) has been inserted into the expression cassette immediately upstream of the start codon of the neomycin phosphotransferase ORF. Intervening sequences (IVS) accompany the transcription complex (P-40cDNA and neomycin phosphotransferase gene) for maximal expression of mature transcripts. The pCIN4P-40 vector can be used to generate stable transfectants.

Figure 8 shows the expression of P-40 (or annexin I) in MCF-7 stable transfectants. The expression level of P-40 was determined by Western blot and indirect immunofluorescence. Figure 8a shows equal number of cells from MCF-7 transfected with vector alone (lane 1) or vector plus P-40cDNA (P-40-MCF-7) (lane 2) were lysed and the total lysates were separated by 10% SDS PAGE and blotted onto PVDF membrane. The blot was probed with IPM96 monoclonal antibody. Figure 8b shows immunohistochemical staining of MCF-7 cells transfected with vector alone or vector plus P-40cDNA. The expression of P-40 (or annexin I) is stable transfectants (P-40-MCF-7) was determined using the cytopspins probed with IPM96 mAb and FITC conjugated goat anti-mouse secondary antibody as described in Materials and Methods. Figure 8b shows the expression of P-40/annexin I by immunofluorescence analysis using the IPM96 mAb.

Figure 9 shows the effects of anticancer drugs on MCF-7 cells stably expressing P-40 (or annexin I). MCF-cells transfected with P-40 cDNA or vector only, were incubated in the absence and presence of increasing concentration of adriamycin (doxorubicin), actinomycin D, Taxol and cisplatin. The sensitivity of the cells to the drugs was measured by the tetrazolium salt based assay as described in Materials and Methods. Experiments were performed in triplicates.

Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments with reference to the accompanying drawing which is exemplary and should not be interpreted as  
5 limiting the scope of the present invention.

### **DESCRIPTION OF THE PREFERRED EMBODIMENT**

#### **MATERIALS AND METHODS**

##### **10 Cell culture and metabolic labelling**

Drug sensitive ( MCF-7, H69, SKOV3 and HL60) and resistant (MCF-7/Adr, H69/Adr, SKOV3/VLB<sup>1.0</sup> and HL60/AR) cells were grown in the absence of antibiotics in  $\alpha$ -MEM or RPMI-1640 media supplemented with 5% to 15% fetal calf serum (Hyclon. Inc.) as previously described (Mirski et al.,  
15 1987, Cancer Res. 47: 2594-2598; McGrath et al., 1987, Biochem. Biophys. Res. Com. 145(3): 1171-1176; Bradley et al., 1989, Cancer Res. 49: 2790-2796; Batist et al., 1986, J. Biol. Chem. 261(33): 15544-15549). Briefly, cells were grown at 37°C in humid atmosphere of 5% CO<sub>2</sub> and 95% air. Cells were passaged when 70-80% confluent for adherent cells and 1X10<sup>6</sup> cell/ml for cells  
20 in suspension. Drug resistant cells were grown continuously with the appropriate concentrations of cytotoxic drugs 24 hours following subculturing. All cells were examined for *Mycoplasma* contamination using the *Mycoplasma* PCR method (Stratagen Inc. San Diego, CA). For metabolic labeling of cells, MCF-7/Adr cells at 70-80% confluency were metabolically labeled with [<sup>35</sup>S] methionine (100  
25  $\mu$ Ci/ml; 1000 Ci/mmol; Amersham Life Sciences, Inc.) or Carrier free <sup>32</sup>P inorganic phosphate (8 mCi/ml; Amersham Life Sciences, Inc.) for 3-4 hours at 37° C in methionine- or phosphate-free  $\alpha$ -MEM. Cells were lysed and the cell lysates were immunoprecipitated with IgG<sub>2b</sub>, or IPM96 mAb.

**Screening an expression library with IPM96 monoclonal antibody**

A 5' stretch cDNA expression library of HeLa cells constructed into  $\lambda$ gt11 vector was obtained from Clontech (Palo Alto, CA). About  $1 \times 10^6$  plaque forming units were plated using *Escherichia coli* Y1090 as host and screened with IPM96 monoclonal antibody. Briefly, plates containing phage plaques were incubated at 42°C for 4 hours and then overlaid with a dried nitrocellulose filter saturated in 10 mM X-gal. The plates were continuously incubated at 37°C for another 3 hours and the filters were rinsed with TBST buffer (50 mM Tris-HCL pH 7.9, 150 mM NaCl, 0.05% Tween-20) and incubated in TBST containing 5% of skin milk for 30 minutes with gentle agitation. The nitrocellulose disks were incubated with TBST buffer containing 2  $\mu$ g/ml of Protein G purified IPM96 monoclonal antibody. The reactive plaques were detected with a second goat anti-mouse IgG conjugated to horseradish peroxidase and visualized chemiluminescence using Amersham ECL kit. The immunoreactive plaques were verified by duplicate lifts and purified by subsequent rounds of screening using decreased plaque density. Immunoreactive plaques were eluted in ddH<sub>2</sub>O and utilized as template for PCR directed by the 3' and 5' insert screening ampimer sequence of  $\lambda$ gt-11 and the fragment from PCR was cloned into PCR II vector (InVitrogen Inc.) following standard procedures (Sambrook et al., 1989, Molecular cloning: A laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.)

**Nucleotide Sequencing and Computer Sequence Analysis**

The cDNA clones of the present invention were sequenced by the dideoxy chain termination method using M13 universal primer and sequence specific primers via the automated DNA sequencing service at the Sheldon Biotech Centre at McGill University. Both strands of two different pick clones were completely sequenced. Computer analysis of the DNA and protein sequence was done using the Blast DNA search programs.



### Northern blot and DNA slot blot analyses

For Northern blot, total RNAs from drug sensitive and resistant cells were extracted with the Trizol solution (GibcoBRL, Gaithersburg, U.S.A). Approximately 10 µg of RNA from each cell line was run on a 1% formaldehyde-denatured agarose gel and transferred to Hybond<sup>TM</sup>-N nylon membrane (Amersham, Oakvill, Ont.) by pressure blotting with 20X SSC (1X = 140 mM NaCl, 32 mM Sodium Citrate, pH 7.4). The blot was incubated in the presence of 32P labeled P-40 cDNA probe by nick translation or actin gene in 50% formamid, 2.5X Denhardt's solution, 25 mg/ml denatured Salmon sperm DNA, 1% SDS and 1.25X SSPE overnight. The blot was washed in low stringency wash with 0.5X SSC for 30 minute at room temperature. A higher stringency wash was applied only if it was necessary. RNA integrity and equal loading was assessed in all cases by hybridization with actin or rRNA probes. Quantification of radioactive signals was carried out by scanning the resultant autoradiography and analysis with NIH imaging software (Wayne, 1992, NIH Imaging Software ).

For slot blotting, genomic DNA from MCF-7 and MCF-7/Adr cells was prepared as described (Sambrook et al., 1989, *supra*) and 10 µg DNA from each sample was denatured by 1 M NaOH. Following 10 minute boiling at 100°C. The denatured DNA was diluted serially loaded onto Nylon membrane by using Manifold Slot Blot apparatus (Pharmacia Inc.). The blot was then hybridized with a 32P-labeled probe at 42°C in 50% formamide, 2.5X Denhardt's solution, 25 mg/ml denatured salmon sperm DNA, 1% SDS and 1.25X SSPE overnight. The highest stringent wash of the blot was 0.5X SSC with 1% SDS at 65°C for 30 minutes.

### In vitro Translation and Immunoprecipitation

*In vitro* transcription and translation reactions were carried out using a rabbit reticulocyte lysate (Promega Corporation, Madison, WI) and 35S-methionine (Dupont/NEW, Mississauga, Ont.) according to the manufacturer's protocol. Briefly, cDNA clone encoding full length P-40 was

cloned into NotI and XhoI sites of a pCDNA3 expression vector containing T7 and SP6 promotor sequences (In VitroGene, Inc.). The pCDNA3 with and without P-40 insert were added to a coupled reticulocyte lysate transcription and translation system in the presence of [35S]-methionine. Following a 2 hour incubation at 30°C, *in vitro* synthesized proteins were immunoprecipitated with IPM96 monoclonal antibody as previously described (Georges et al., 1991, J. Cell. Physiol. 148: 479-484; Wang et al., 1997, *supra*).

#### **DNA Transfection**

MCF-7 cells were transfected with the pCDNA3 or pCIN4 vectors or vector containing P-40 coding sequence using lipofectAMINE (Gibco, Burlington, Ontario, Canada) according to the manufacturer's procedure. Briefly, 4 X 10<sup>5</sup> cells in a 60 mm plate with 5 ml of serum-free minimal essential medium were overlaid with 200 µl of serum-free essential medium containing 5 µg of supercoiled DNA mixed with 10 µl of lipofectAMINE. After 5 hour incubation, the medium was replaced with 5 ml of minimal essential medium (MEM) supplemented with 10% fetal calf serum (Hyclone Laboratories) and cells were further cultured at 37°C for 24 - 48 hours. For the transient transfection, cells were collected and the expression of P-40 was detected by western blot and immuno- fluorescence. For stable transfectants, G418 was added to the cells at 1 mg/ml and continuously selected for another two-three weeks. The individual transfectant clones of MCF-7 cells were obtained by the limited dilution under the G418 treatment (i.e. pCIN4-P40 and PCIN4 stably expressing cells). A population exhibiting highly expressed P-40, designated BM-1, and a population of the cells transfected with pCDNA3 alone, designated Aivi-1 were expanded for further analysis by Western blot or immunoprecipitation. A population of cells exhibiting high stable expression of P-40 and a population of the cells transfected with pCIN4 vector alone were characterized by Western blotting and immunofluorescence.

**Immunofluorescence Staining of Cells**

Cells were washed with PBS and smeared onto glass slides by brief centrifugation at 1,500 rpm. The cytopins were air-dried and fixed for 10 minutes in ice-cold acetone. Cells were rinsed twice with PBS and incubated in 1% bovine serum albumin (BSA)/PBS for 30 minutes at room temperature. Slides were incubated with the IPM96 mAb (5 µg/ml 1% BSA/PBS) for 30 minutes followed by three two minutes rinses with PBS. FITC-conjugated goat-anti-mouse IgG (1:50 dilution) was added to slides and allowed to incubate for 30 minutes. After several washes, slides were mounted in PBS containing 50% glycerol and examined with a Nikon UFX-DX fluorescent microscope fitted with a 60X oil immersion objective. Photographs were taken with Kodak Tri-X pan film (400 ASA) at 800X magnification.

**Drug Sensitivity Assay**

Transient transfectants were harvested 48 hours later and aliquoted at  $7.5 \times 10^3$  cells per well of a 96-well plate. Drugs were added to cells 24 hours later and incubated for another 48 hours at 37°C. The assay was developed by adding 50 µl (5 mg/ml) of an MTT dye and allowed to incubate for four hours at 37°C as previously described (Pouliot et al., 1997, *Biochem. Pharmacol.* 53(1): 17-25).

**SDS-PAGE and Western Blotting**

Total cell lysates cell cultures or from transcription/translation reaction mixture were mixed with equal volumes of sample buffer containing SDS and the denatured proteins were resolved on 10% polyacrylamide gels according to the method of Laemmli (Laemmli et al., 1970, *Nature* 227(259): 680-685). For acrylamide gels containing <sup>35</sup>S-methionine labeled proteins, gels were fixed in 50% methanol/water and soaked in Amplify<sup>TM</sup> (Amersham, Oakvill , Ont.) for 30 minutes prior to drying and exposing to Kodak film at -70°C. For Western blot analysis, proteins were transferred to nitrocellulose membrane

for 1 hour at 50 volts according to the method of Towbin et al., (Towbin et al., 1979, Proc. National Acad. of Sciences of the United States of America 76(9): 4350-4354). The nitrocellulose membrane was blocked with 5% skin milk/PBS and incubated overnight at 4°C with 1 µg/ml of IPM96 monoclonal antibody. The immunoreactive proteins were detected with horseradish peroxidase conjugated goat anti-mouse antibody and visualized by chemoluminescence using Amersham ECL kit (Amersham, Oakville, Ont.).

#### **Cytotoxicity assays**

The chemosensitivity patterns of stably transfected MCF-7 cells with pCIN4 vector alone or full length P-40 cDNA were determined by a tetrazolium salt-based microplate assay as described previously (Pouliot et al., 1997). Briefly, 100 µl aliquots of cells were plated into 96-well plates at 5000 cells per well. The cells were then incubated at 37° C for 24 hours before the addition of increasing concentration of different cytotoxic agents. Following a 72 hour incubation with different anticancer agents, 3-(4,5-Demethylthiazol-2-yl)-5-diphenyl-tetrazolium bromide (Sigma) was added to each well of the plates at a final concentration of 2.5 mg/ml. After 4 hour incubation, cells were solubilized by the addition of 50 µl of 10% Triton X-100 in 0.01 N HCl. The 96-well plates were heated in the microwave oven for 1 minute at the minimal power setting, and 10 µl of 100% ethanol was added to disperse the bubbles formed during pipeting. Plates were read at 570 nm using an ELISA microplate reader. The effects of drugs on the viability of cells were expressed as the mean ± SD of two to three independent experiments in which triplicates were assayed.

## **RESULTS**

### **Isolation and characterization of P-40 cDNA clones**

In a previous report (Wang et al., 1997, *supra*), we had demonstrated the overexpression of a 40 kDa protein (P-40) in several MDR cell lines alone or together with P-gp and MRP. In this study, we have used the

monoclonal antibody IPM96 which binds specifically to P-40 to screen a cDNA expression library made from HeLa cells. A total of 50,000 plaques were screened and several positive plaques were identified following the initial screening. Of the latter positive plaques two positive clones were obtained after  
5 sequential plaque purification and both inserts were isolated by PCR (see Material and Methods). Both positive clones encoded for a 1.6 kb fragments that were subsequently cloned into a T/A PCRII vector. Sequence analysis of both clones showed an open reading frame of 346 amino acids which is consistent with the molecular mass of the protein (38.7 kDa versus 40 kDa) (figure 1A).  
10 Comparison of P-40 nucleotide and amino acid sequences (figures 1B and 1C) to other sequences in the DNA data bank, using the DNA search programs Tblast, showed it to be identical to Annexin I sequence (Wallner et al., 1986, Nature 320: 77-81).

To confirm the identify of the isolated cDNA, a 1.4 kb  
15 encoding the full length of P-40 (Annexin I) was expressed *in vitro* using T7 promotor directed transcription-translation reticulocyte lysate with <sup>35</sup>S-methionine. Figure 2a shows the immuno- precipitation of proteins with IPM96 mAb from an *in vitro* expression reactions containing vector only (lane 1) or vector plus 1.4 kb insert (lane 2). As a control for the IPM96 antibody, an  
20 irrelevant IgG2b was used to immunoprecipitate proteins from a reaction mix containing vector plus the 1.4 kb insert (figure 2a, lane 3). The results of figure 2a show a <sup>35</sup>S-methionine labeled 40 kDa protein immunoprecipitated with IPM96 mAb but not with an irrelevant IgG2b (lanes 2 and 3, respectively). Figure 2b, also shows Western blotting of the proteins identical to those in lanes 1 and  
25 2 of figure 2a, but probed with IPM96 mAb (lanes 1 and 2) or an irrelevant IgG2b (lanes 3 and 4). Taken together, these results confirm the identity of the 1.4 kb fragment as the gene encoding P-40 or Annexin I.

To determine if the amino acid sequence of P-40 (or Annexin I) cloned from HeLa cells is similar or different from that found in  
30 MCF-7/AR cells, Annexin I was cloned from MCF-7/AR cells by reverse PCR

using 5' and 3' primers encoding Annexin I. Sequence analysis of Annexin I clones from MCF-7/AR cells revealed no differences from that isolated from HeLa cells cDNA expression library (data not shown).

#### Northern blot analyses

5                                      In an earlier study (Wang et al., 1997, *supra*) , the levels of P-40 was compared between drug sensitive and resistant cell lines. Figure 3a shows a Western blot analysis of total cell lysates from drug sensitive (MCF-7, SKOV3 and H69) and their resistant (MCF-7/AR, SKOV3/VLB<sup>1.0</sup> and H69/AR) cells probed with IPM96 mAb. The results of the latter Western blot analysis  
10 shows clearly the increase in P-40 expression in resistant cells relative to the parental drug sensitive cells. The SKOV3 cells show lower levels of P-40 than the resistant SKOV3/VLB<sup>1.0</sup>. However, it is interesting that the SKOV3 cell line was derived from a patient with ovarian tumor that was considered to be clinically resistant Cis-platinum and adriamycin [(ogh et al., 1975, Plenum  
15 Press, New York : 155-159). To determine if the increase in P-40 or Annexin I protein expression in the above MDR cells is due to an increase in mRNA levels, Northern blot analysis were performed with total RNA extracted from drug sensitive (MCF-7, SKOV3 and H69) and resistant (MCF-7/AR, SKOV3/VLB<sup>1.0</sup> and H69/AR) cells and blotted membrane probed with a 32P labeled 1.4 kb  
20 fragment. The results in figure 3b shows the 1.8 kb mRNA band in resistant MCF-7/AR and H69/AR but not in the parental drug sensitive cell lines, MCF-7 and H69/AR. The level of 1.8 kb mRNA hybridizing band was 4-fold higher drug resistant SKOV/VLB<sup>1.0</sup> cells relative to drug sensitive SKOV-3 cells (figure 3b). Taken together, the Northern blot demonstrate clearly that the observed  
25 increase in P-40 or Annexin I cells is due to an increase in mRNA of P-40. Furthermore, the Northern blot results are consistent with the Western blot data, especially those relating to the protein and mRNA levels of P40 or Annexin I in SKOV3 versus SKOV3/VLB<sup>1.0</sup> cells (figure 3).

30                                      To determine if the above increase in mRNA levels in MDR cells relative to drug sensitive cells is at the transcriptional level or is due to gene

amplification, genomic DNA was isolated from the above cells lines and analyzed quantitatively using slot blot. The results (data not shown) show no gene amplification for P-40 or Annexin I between drug sensitive and resistant cells.

#### 5 **Post-translational modification of P-40 or Annexin I in resistant cells**

Annexin I is a phosphoprotein phosphorylated at serine and tyrosine amino acids (Wang et al., 1994, *Biochem.*, 33: 276-282; Varticovski et al., 1988, *Biochem.*, 27: 3682-3690). Further, it has been shown that phosphorylation of Annexin I at its N-terminal domain decreases its affinity for negatively charged phospholipids or membrane vesicle aggregation (Wang et al., 1994, *Biochem.*, 33: 276-282 ]. Given the above results, it was of interest to examine the post-translational modification of P-40 or Annexin I in MDR cells. The results in figure 4 show immuno-precipitation of P-40 or Annexin I with an irrelevant IgG2b or IPM96 mAb from MCF-7/AR cells that have been metabolically labeled with 35-methionine (lanes 1 and 2) or 32P inorganic phosphate (lanes 3 and 4). Interestingly, P-40 or Annexin I was not phosphorylated in MCF-7/AR cells. Similarly, it was not possible to demonstrate basal level of P-40 or Annexin I phosphorylation in the other MDR cells (data not shown).

#### 20 **Overexpression of Annexins II and IV in MDR cells**

To determine if other members of the annexin family are similarly overexpressed in MDR cells relative to the parental drug sensitive cells, total cell proteins from drug sensitive (MCF-7, H69 and SKOV3) and resistant (MCF-7/AR, H69/AR and SKOV3/VLB<sup>100</sup>) cells were separated by SDS-PAGE and transferred to nitrocellulose membrane. Figure 5 shows the results of the Western blots probed with anti-Annexin I, II, IV and VI monoclonal antibodies. The results of the Western blot probed with anti-Annexin I show similar results to the Western blot in figure 3a probed with IPM96, confirming the antigen specificity of IPM96 mAb towards to Annexin I. Furthermore, the expression of Annexin II and IV is also increased in MDR cells relative to the parental cell

lines, however to a lesser extent as that of Annexin I. However, unlike annexin I, both annexin II and IV are expressed, at lower levels, in drug sensitive cells (figure 5). Of considerable interest is the levels of Annexin I, II and IV in a revertant cell line (H69/PR) derived from H69/AR cells that are less resistant to doxorubicin (figure 5). cDNA transfections (transient and stable) of Annexins II-XI, as described below will be carried out to verify the drug resistance of Annexin II-XI-transfected cells.

#### **cDNA transfection and drug sensitivity analyses**

In an attempt to investigate the role of P-40 or Annexin I overexpression in drug resistance, the full length gene encoding P-40 or Annexin I was cloned into a mammalian expression vector, pCDNA3 and transfected into MCF-7 cells. MCF-7 cells transfected transiently with pCDNA3 alone or with P-40 gene are cultured for 3 days prior to analysis. The results in figure 6a show a Western blotting of total cell proteins from MCF-7 cells transfected with pCDNA3 vector only or pCDNA3 vector plus P-40 or Annexin I gene (lanes 2 and 3). The results in lane 3 of figure 6a show a 40 kDa protein in MCF-7 cells transfected with pCDNA3 vector plus P-40 or Annexin I. To determine more quantitatively, the level of P-40 transfection following a three day culturing, MCF-7 cells transfected with pCDNA3 plus P-40 or Annexin I full length cDNA were analyzed by indirect immunofluorescence with IPM96 mAb. The results in figure 6b showed the relative number (<5%) of MCF-7 cells that overexpress P-40 or Annexin I. The efficiency of the transient transfection to ~5% of the cells was confirmed following transfection with pCDNA3 containing a beta-gal gene (data not shown).

Having established the expression of P-40 or Annexin I in MCF-7 cells, it was of interest to examine the effect of P-40 or Annexin I overexpression (albeit <5%) on the sensitivity of MCF-7 cells to anticancer drugs. The results in figure 6b and 6c show MCF-7 cells transfected with vector only and with vector plus P-40 incubated with increasing concentrations of Taxol or adriamycin, respectively. Surprisingly, overexpression of P-40 or Annexin I in



MCF-7 cells decreases their sensitivity to Taxol and adriamycin. The analysis as to whether higher levels of P-40 or Annexin I expression will lead to a larger decrease in the sensitivity of transfectant cells to anticancer drugs has also been formerly tested using for stable cell lines expressing P-40-cDNA (see below).

5                   The transient transfected cells were incubated with a chelator (EGTA) or a calcium channel blocker (Verapamil). P-40-protein was shown to be released by the membrane and the EGTA or Verapamil-treated cells were also shown to have reduced drug resistance to taxol or adriamycin. These results suggest that small molecules find utility in the context of the present  
10                   invention.

## DISCUSSION

In this study we have used the monoclonal antibody IPM96, previously shown to detect a 40 kDa protein in MDR cells to screen a  $\lambda$ gt11  
15                   expression library. Two positive  $\lambda$ gt11 clones were identified and their cDNA insert was isolated by PCR and cloned into a TA PCRII vector. Analysis of the nucleotide and amino acid sequence of the 1.4 kb cDNA insert revealed an open reading frame of 346 amino acids that is identical to Annexin I, a known substrate of epidermal growth factor receptor (Wallner et al., 1986, Nature  
20                   320: 77-81). *In vitro* expression of IMP96 positive cDNA clone using a transcription-translation retic, lysate followed by immuno precipitation and Western blot analyses of the expressed 40 kDa protein confirmed the identify of the 1.4 kb fragment as P-40. In addition, Northern blot analysis using total RNA from drug sensitive and resistant cells confirmed the overexpression of  
25                   Annexin I or P-40 mRNA in MDR cells relative to their parental drug sensitive cells.

Besides the similarities in the P-40 and Annexin I molecule masses on SDS-PAGE and the cross-reaction of IPM96 with Annexin I expressed *in vitro*, the identity of the P-40 as Annexin I is consistent with our  
30                   earlier observations where P-40 was shown to be found both in the membrane

and soluble fractions (Wang et al., 1997, *supra*). Furthermore, extraction of membrane associated P-40 was resistant to high salt and EDTA and suggests the possibility that some of P-40 may be an integral membrane protein. Interestingly, a similar conclusion was independently suggested for Annexin I in an earlier study . The latter possibility is likely given that annexins I, V, VI and VII possess ion channel activity (Pollard et al., 1988, Proc. Natl. Acad. Sci. USA 85: 2974-2978; Rojas et al., 1990, J. Biol. Chem. 265(24239-24245)). Also consistent with our assignment of P-40 as Annexin I, is the fact that the 35 kDa proteolytic product which has been previously demonstrated to represent the head domain of Annexin I, is highly sensitive to proteolysis (Wang et al., 1994, *supra*).

We have previously shown that P-40 (or annexin I) is highly expressed in several MDR cell lines relative to their parental drug sensitive cells (Wang et al., 1997, *supra*). The MDR cell lines used in our study were previously shown to contain amplified copies of Pgp MDR-1 or MRP genes. The genes encoding Pgp, MRP and P-40 (or annexin I) are localized on chromosome 7, 16 and 9 respectively (Cole et al., 1993, *supra*; Trent and Witkowski, 1987, *supra*; Wallner et al., 1986, *supra*). Therefore, the observed increase in P-40 protein is not due to a co-amplification of P-gp or MRP. In addition, our Slot blot results did not reveal the amplification of P-40 (or annexin I) gene in any of the MDR cell lines where P-gp or MRP are amplified. Furthermore, P-40 (or annexin I) was detected in MDR cell lines that lacked detectable P-gp or MRP. The northern blot analysis of total RNA from drug sensitive and resistant cells revealed an increase in P-40 (or annexin I) mRNA levels in drug resistant cells. Thus, the observed increase in P-40 (or annexin I) protein level in resistant cells is transcriptionally regulated. Alternatively, the increased transcription or mRNA stabilization may govern the overexpression of P-40 in MDR cells. Of interest was the detectable increase in P-40 (or annexin I) mRNA in SKOV3 drug sensitive cells versus that in other drug sensitive cells. However, P-40 (or annexin I) mRNA in SKOV3 cells was four

fold less than that in its drug resistant counterpart (SKOV/VLB<sup>1.0</sup>). In particular, the northern blot results are consistent with the Western blot data, especially those relating to the protein and mRNA levels of P-40 or annexin I in SKOV3 compared with (SKOV/VLB<sup>1.0</sup>).

5                   The observed decrease in P-40 (or annexin I) expression in a revertant cell line (H69/PR ) derived from H69/AR (Cole et al., 1992) together with the increase in P-40 in (SKOV/VLB<sup>1.0</sup>) following *in vitro* selection from SKOV3 show a strong correlation between the overexpression of P-40 (or annexin I) and MDR.

10                   Annexin I is a member of a large family of calcium dependent membrane binding proteins that are sometimes referred to as lipocortin, calpectins, endonexins (for review see Raynal et al., 1994, Bioch. Biophys. Acta. 1197: 63-93). Annexins share a similar core domain with four or eight conserved 70 amino acid repeats and an amino terminal domain that varies in  
15                   length and sequence between the different members of the annexin family. Although the physiological function(s) of annexins is not clear, they have been implicated in calcium-regulated exocytosis (Drust et al., 1988, Nature 331: 88-91; Creutz et al., 1987, J. Biol. Chem. 262: 1860-1865). Annexin I has also been shown to mediate the calcium-dependent fusion of liposomes with isolated  
20                   neutrophil plasma membranes (Meers et al., 1986, Nature 321: 81-84).

In intact cells, annexins are generally phosphorylated in response to varieties of stimuli. Annexin I is phosphorylated by EGF receptor-kinase at tyrosine residues found in the N-terminal head domain (Pepinsky et al., 1986, Nature 321: 81-84) and by protein kinases C and A (Varticovski et al., 1988, Biochem. 27: 3682-3690]. Interestingly, phosphorylation of Annexin I at the amino terminal domain  
25                   by protein kinase C inhibits its ability to aggregate chromaffin granules (Wang et al., 1986, J. Biol. Chem. 261: 6548-6553.). In adrenal chromaffin cells, Annexin I was shown to be rapidly phosphorylated upon stimulation of cells to secrete normal cell metabolites Wang et al. 1992, Biochem, 31: 9934-9939)

Taken together, our finding that Annexin I is not phosphorylated in MDR cells is consistent with its increased capacity to cause aggregation of membrane vesicles.

In this report we show, for the first time, a direct role of  
5 Annexin I overexpression in tumor cells resistance to anticancer drugs. Using transient transfections of MCF-7 tumor cells, we showed that transfection of P-40 or Annexin I cDNA confers resistance to Taxol and adriamycin. Although the levels of resistance towards the latter drugs are only 1.2 to 2.0-fold more than control cells (transfected with vector alone), the results are consistent and  
10 are not surprising in light of the percentage (<5%) of transfected cells (figure 6a and data not shown). Furthermore, similar transfection studies of P-gp or MRP cDNA have also shown much lower levels of drug resistant in transfectant cells when compared to selected MDR cells that overexpress similar amounts of these proteins (Zaman et al., 1994, Proc. Nat. Acad. Sc. USA 91(19): 8822-  
15 8826; Cole et al., 1994, Cancer Res. 54(22): 5902-5910; Gros et al., 1986, Nature 323: 728-731).

In this study, it is shown that the level of drug resistance of P-40 (or annexin I) transfectants is 2 to 3 fold higher than the transfected with vector alone. It is thus likely that P-40 (or annexin I) confers lower level of drug  
20 resistance than P-gp or MRP (3 to 8 fold). However, unlike the high levels of drug resistance seen in *in vitro* drug selected MDR tumour cell lines, low level of drug resistance conferred by different cellular changes (such as P-40) are likely to be clinically relevant. Given the fact that P-40 is expressed at lower level in SKOV3 cells, which are clinically resistant to adriamycin and cisplatin,  
25 than that of SKOV/VLB<sup>1.0</sup> (1000 fold resistance to vinblastine), it is submitted that the observed overexpression of P-40 (or annexin I) is probably an early event in the development of clinical drug resistance. Work is in progress in the investigation of P-40 in clinical tumour samples.

In this study, it is shown, for the first time, that P-40 (or  
30 annexin I) confers resistance to anticancer drugs. The results from the

cytotoxicity assays indicate that the drug resistance profile of P-40 (or annexin I) transfectants is similar, but not identical to P-gp or MRP transfectant cells. This apparent difference in the resistance spectrum may be important to the mechanism of P-40 (or annexin I) mediated drug resistance. The mechanism by which P-40 (annexin I) confers drug resistance to anticancer drugs is presently unknown. However, the fact that P-40 cannot be labelled by photoactive analogues of cytotoxic agents (data not shown) and that its amino acid sequence does not encode an ATP binding domain suggest that P-40 (or annexin I) itself does not transport drugs directly to the extracellular environment. The intracellular distribution of P-40 in both *in vitro* selected P-40 expressing cells and in the transfectant cells suggests that the membrane localization of P-40 (annexin I) is essential for its function in drug resistance. Translocation of P-40 from the plasma membrane to cytoplasm after treatment with verapamil and EDTA has been observed in both P-40 expressing cell lines and P-40 cDNA transfectants (data not shown). This finding suggests that P-40 may participate in sequestering drugs from their targets. Alternatively, the intracellular action concentration (eg.  $\text{Ca}^{2+}$ ) may be important for the functions of P-40 (annexin I) in drug resistance. Work is in progress to determine if P-40 induced drug resistance can be reversed by MDR modulators. Given the role of annexins in promoting aggregation of membrane vesicles through  $\text{Ca}^{2+}$  dependent phospholipid binding, it is proposed that P-40 (annexin I) confers a drug resistance phenotype by aggregation of drug filled membrane vesicles or exocytosis of such drug filled vesicles (Chauffert et al., Cancer Res. 46: 825-830). The observed increase in membrane vacuolisation in many MDR cell lines (Beck, 1987, Biochem. Pharmacol. 36(18): 2879-2887; Sehested et al., 1987 British J. of Cancer 56: 747-751) supports this proposition. Furthermore, P-glycoprotein and MRP have been detected in the endosomal membranes in *in vitro* selected cell lines (Abbaszadegan et al., 1997, Cancer Res. 56(23): 5435-5442; Klohs et al., 1988, Mol. Pharmacol. 34: 180-185). Thus, P-40 (or annexin I) or other members of the annexin family could function together with P-

glycoprotein or MRP to cause the aggregation and possibly exocytosis of drug filled vesicles. Whatever, the mechanism of action of annexins and more particularly of annexin I, the present invention strongly suggests their importance in the establishment of the MDR phenotype in cancer cells. The present invention presents means to further dissect the structure/function relationship of annexins in MDR and provides methods and assays to identify modulators of this MDR phenotype.

The present invention is described in further detail in the following non-limiting examples.

#### EXAMPLE 1

##### Characterization of P-40 (or annexin I) MCF-7 stable transfectant cells

To determine if P-40 (or annexin I) alone confers resistance to anticancer drugs, a full length cDNA clone of P-40 (or annexin I) was cloned into pCIN4 eukaryotic expression vector (Figure 7) and transfected into MCF-7 drug sensitive cells. Stable transfectants of P-40 (or annexin I) MCF-7 cells (P-40-MCF-7) were selected in the presence of lethal concentration of G418. Figure 8a shows a Western blot analysis of lysates from P-40-MCF-7 cells probed with the IPM96 monoclonal antibody. The results of the latter western blot shows that P-40 MCF-7 cells express 1/3 less P-40 than the MDR *in vitro* selected MCF-7/Adr cells. However, the distribution pattern of P-40 (or annexin I) in P-40-MCF-7 transfectants is similar to that in MCF-7/Adr cells (Figure 8b). As expected, no detectable levels of P-40 was observed in cells transfected with vector alone.

#### EXAMPLE 2

##### Cross resistance patterns of P-40 MCF-7 stable transfectants

Having established the expression of P-40 (or annexin I) in P-40-MCF-7 cells, it was of interest to know the effect of P-40 (or annexin I) on the sensitivity of MCF-7 cells to anticancer drugs. Figure 9 shows the results of

the chemosensitivity assays using P-40-MCF-7 cells in the presence of increasing concentration of anticancer drugs to that of MCF-7 cells transfected with vector alone. Surprisingly, P-40-MCF-7 cells displayed low level of resistance to adriamycin, actinomycin D, Taxol and cisplatin (Figure 9) relative to the cells transfected with vector alone. However, P-40-MCF-7 cells did not show cross-resistance to colchicine and vincristine (data not shown). These results suggest that the overexpression of P-40 (or annexin I) does confer a low level of drug resistance to a variety of anticancer drugs.

In conclusion, the present invention provides convincing evidence that annexin and particularly annexin I are important in the development of the MDR phenotype in cancer cells. The herein presented findings are also important for providing a further understanding of the functions of the annexin family. Analysis of clinical tumour samples for P-40 (or annexin I) expression (primary or relapsed after chemotherapy) will provide further evidence for the diagnostic role of P-40 in clinical drug resistance.

The present description refers to a number of documents, the content of which is herein incorporated by reference.

Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule encoding an Annexin family member, a member of the multidrug resistance (MDR) gene family for assessing or modulating MDR in a cell.  
5
2. The isolated nucleic acid molecule of claim 1, wherein said cell is selected from an animal cell, mammalian cell, a human cell, a parasitic cell and a fungal cell.  
10
3. The isolated nucleic acid molecule of claim 1, comprising a nucleic acid sequence which is at least 90% identical to a sequence selected from the group consisting of a nucleotide sequence encoding an Annexin polypeptide selected from Annexin I to Annexin XI, or a nucleotide sequence complementary thereto.  
15
4. The isolated nucleic acid molecule of claim 1, 2 or 3, wherein said Annexin is Annexin I and said Annexin polypeptide is the Annexin I polypeptide which comprises the complete amino acid sequence set forth in Figure 1C.  
20
5. The isolated nucleic acid molecule of claim 1 or 2, wherein said Annexin is Annexin I and said nucleotide sequence comprises the nucleotide sequence as set forth in Figure 1B.  
25
6. A method of detecting and/or assessing Annexin-based MDR in a sample comprising:



- a) contacting said sample with an isolated nucleic acid molecule consisting of 10 to 50 nucleotides specifically hybridizing to RNA and/or DNA encoding an Annexin, wherein said nucleic acid molecule is or is complementary to a nucleotide sequence consisting of at least 10 consecutive nucleotides from the nucleic acid sequence of one of Annexin I to XI, under hybridization conditions; and
- b) detecting the presence of said molecule bound to Annexin nucleic acid.
7. A kit for detecting and/or quantifying an Annexin nucleic acid in a sample comprising at least one container means having disposed therein an isolated nucleic acid molecule consisting of 10 to 50 nucleotides specifically hybridizing to RNA and/or DNA encoding an Annexin, wherein said nucleic acid molecule is or is complementary to a nucleotide sequence consisting of at least 10 consecutive nucleotides from the nucleic acid sequence of one of Annexin I to XI.
8. A recombinant vector for modulating and/or inhibiting and/or increasing Annexin-based MDR in a cell comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter element.
9. The recombinant vector of claim 8, wherein Annexin is Annexin I.
10. The recombinant vector of claim 9, being pCDNA3/P-40 or pC1N4P-40.

11. A cell that contains the recombinant vector of claim 8 or  
9.

12. A method of identifying compounds that affect  
5 Annexin-based MDR, said method comprising:  
a) incubating the cell of claim 11 in the presence of a  
potential Annexin-based MDR-affecting compound in the presence and absence  
of a drug; and  
b) assessing the effect of said compound on the resistance  
10 to said drug.

13. The method of claim 12, wherein said compound is  
selected from the group consisting of a nucleic acid molecule, a dominant  
negative mutant of an Annexin, a mutant Annexin, an antibody to Annexin, a  
15 peptide, and a small molecule.

14. The method of claim 13, wherein said compound is an  
Annexin I antisense molecule.

20 15. A method of reducing Annexin-based MDR in a cell  
comprising: administering thereto a therapeutically effective amount of a  
compound selected from the group consisting of a nucleic acid molecule, a  
dominant negative mutant of an Annexin, a mutant Annexin, an antibody to  
Annexin, a peptide, and a small molecule.

25

16. The method of claim 15, wherein said compound is an  
Annexin I antisense molecule.

17. The method of claim 15, wherein said compound is a calcium chelator or a calcium channel blocker.

18. A pharmaceutical composition for reducing MDR in a cell  
5 comprising an Annexin-based MDR affecting compound together with a suitable pharmaceutically acceptable carrier.

19. A method of diagnosing the presence or predisposition of Annexin-based MDR in a patient comprising:

- 10           a) taking a sample from said patient;  
             b) determining the amount of Annexin protein and/or RNA in said sample;  
             c) diagnosing the presence or predisposition of Annexin-based MDR in said patient, wherein an increased amount of said  
15 Annexin protein and/or RNA in said sample as compared to a control sample indicates the presence or predisposition towards Annexin-based MDR.

20. A method of diagnosing the presence or predisposition of Annexin-based MDR in a pathogen comprising:

- 20           a) taking a sample from said pathogen;  
             b) determining the amount of Annexin protein and/or RNA in said sample;  
             c) diagnosing the presence or predisposition of Annexin-based MDR in said pathogen, wherein an increased amount of said  
25 Annexin protein and/or RNA in said sample as compared to a control sample indicates the presence or predisposition towards Annexin-based MDR.

1/17

Restriction map of the gene encoding for P-40




FIG. 1A

2/17

## ORIGIN

1 agtgtgaaat ctacagagaa gaatttctct ttagttcttt gcaagaagggt agagataaag  
 61 acactttttc aaaaatggca atggtatcag aattcctcaa gcaggcctgg ttatttgaaa  
 121 atgaagagca ggaatatgtt caaactgtga agtcatccaa aggtgggtccc ggatcagcgg  
 181 tgagccccta tctaccttc aatccatcct cggatgtcgc tgccttgcat aaggccataa  
 241 tgggttaaagg tctggatgaa gcaaccatca ttgacattct aactaagcga aacaatgcac  
 301 agcgtcaaca gatcaaaagca gcatactcc aggaacacagg aaagccctg gatgaaacac  
 361 ttaagaaagc ccttacagggt caccttgagg aggttggttt agctctgcta aaactccag  
 421 cgcaatttga tcttgatgaa ctctgtgctg ccatgaaggg ccttggaact gatgaagata  
 481 ctctaattga gatctttggca tcaagaacta acaagaaat cagagacatt aacagggtct  
 541 acagagagga actgaagaga gatctggcca aagacataac ctacagacaca tctggagatt  
 601 ttcgggaacgc ttgctttct ctgctaagg gtgaccgac tgaggacttt ggtgtgaatg  
 661 aagacttggc tcatcagat gccagggcct tgtatgaagc aggagaaagg agaaagggga

~~FILE~~ - 1B

3/17

```

721 cagacgtaaa cgtgttcaat accatcctta ccaccagaag ctatccacaa cttcgcagag
781 tgttttcagaa atacaccaag tacagtaagc atgacatgaa caaagtcttg gacctggagt
841 tgaagggtga cattgagaaa agagaagctt catcaagcca tgcctcacag ctatcgtgaa gtgcgccaca agcaaaccag
901 ctttcttttg cgtgttcaat accatcctta ccaccagaag ctatccacaa cttcgcagag
961 tgatcaggat tatgggtttcc cgttctgaaa ttgacatgaa tgatatcaaa gcattctatc
1021 agaagatgta tggatatctcc ctttgccaag ccaccagaag ctatccacaa ggagattatg
1081 agaaaatcct ggtgggtctctt tggggaggaa actaaacatt cccttgatgg tctcaagcta
1141 tgatcagaag actttaatta tataatttca tcctataagc ttaaataagg aagtttcttc
1201 aacaggatta cagtgtagct acctacatgc tgaaaaaatat agcctttaaa tcatttttat
1261 attataactc tgtataaatag agataagtcc attttttaaa aatggtttcc ccaaaccata
1321 aaaccctata caagttgttc tagtaacaat acatgagaaa gatgtctatg tagctgaaaa
1381 taaaatgacg tcacaagac

```

//

~~FIG. 1~~

4/17

MAMVSEFLKQAWFJENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAAALHKAIMVK  
GVDEATIIDILTKFNNAQRQQIKAAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPA  
QFDADELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDIAKDTSDTSG  
DFRNALLSLAKGDRSEDFGVNEDLADSDARALYEAGERRKGTDVNVFNTIILTTRSYPQ  
LRRVFQKYTKYSKFDMNKNVLDLELKGDIKCLTAIVKCATSKPAFFAEKLBHQAMKGVG  
TRHKALIRIMVSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN

~~SECRET~~ - 10

5/17

3' GTAGCGACCGCGCTCAGCTGGAATTCCGGCGCGCTCGATTTTGTCTTGTGACGTCAATTTATT  
 5' CATCGCTGGCGCGAGTCGACCTTAAGCGCGCGCGCAGCTAAAAAACAAGAACACTGCAGTAAATAA  
 A T G A Q L E F A A A S I F L S C D V I L F>  
 \* R P A L S W N S R P R R F F C L V T S F Y>  
 S D R R S A G I R G R V D F F V L \* R H F I>  
 <Y R G A S L Q F E R G R R N K Q R T V D N \* K  
 <A V P A \* S S N A A A D I K K D Q S T M K N  
 <L S R R E A P I R P R T S K K T K H R \* K I

70 80 90 100 110 120 130  
 \* \* \* \* \*  
 TTCAGCTACATAGCATCTTCTCATGTTACTAGAACAACTTGATAGGGTTTATGTTTGGGAAA  
 AAGTCGATGTATCTGTAGAAAGAGTACAATGATCTTGTGAACATATCCCAAATACCAACCCCTTT  
 S A T \* T S F S C Y \* N N L Y R V L W F G E>  
 F Q L H R H L S H V T R T T C I G F Y G L G K>  
 F S Y I D I F L M L L E Q L V \* G F M V W G K>  
 <\* S C L C R E \* T V L V V Q I P N \* P K P F  
 <E A V Y V D K E H \* \* F L K Y L T K H N P S F  
 <K L \* M S M K R M N S S C S T Y P K I T Q P F

~~FILE~~



6/17

140 \* 150 \* 160 \* 170 \* 180 \* 190 \* 200 \*  
 ACATTTTAAAGGACTTATCTCTATTATACAGAGTTATAATAAATGATTAAAGGCTATA  
 TGTAAGAAATTTTCCCTGAATAGAGATAATATGCTCAATATTATATTTTACTAAATTTCCGATAT  
 N I F K K W T Y L Y Y T E L \* Y K N D L K A I >  
 T F L K N G L I S I I Q S Y N I K M I \* R L Y >  
 H F \* K E D L S L L Y R V I I \* K \* F K G Y >  
 <V N K F F P S I E I I C L \* L I I F I I \* L S Y  
 <M K L F H V \* R \* \* V S N Y Y L F S K F A I  
 <C K \* F I S K D R N Y L T I I Y F H N L P \* I

210 \* 220 \* 230 \* 240 \* 250 \* 260 \* 270 \*  
 TTTTCAGCATGTAGTACACTGTAATCCTGTTGAAGAACTTTCCATTAAAGCTTATAGGAT  
 AAAAGTCGTACATTCATCGATGTGACATTAGGACAACTTCTTTGAAGGATAAAATTCGAATATCCTA  
 F F S M \* V A T L \* S C \* R N F P I \* A Y R M >  
 F. S A C E. \* L H C N P V E E T F L F K L I G >  
 I F Q H V G S Y T V I L L K K L S Y L S L \* D >  
 <K E A H L Y S C Q L G T S S V K R N L S I P H  
 <N K L M Y T A V S Y D Q Q L F K G I \* A \* L I  
 <K \* C T P L \* V T I R N F F S E \* K L K Y S

~~SECRET~~

7/17

280 \* 290 \* 300 \* 310 \* 320 \* 330 \* 340 \*  
 GAAATATATAATTAAAGTCTTCTGATCATAGCTTGAGACCATCAAGGGAATGTTAGTTTCCCTCCAC  
 CTTTATATATAATTTCAGAGAGACTAGTATCGAACTCTGGTAGTTCCTTACAAATCAAAGGAGGTG  
 K I Y N S L L I I A \* D H Q G N V \* F P P >  
 \* K Y I I K V F \* S \* L E T I K G M F S F L H >  
 E N I \* L K S S D H S L R P S R E C L V S S T >  
 <F Y I I L T K Q D Y S S V M L P I N L K R W  
 <F I Y L \* L R R I M A Q S W \* P F T \* N G G C  
 <S F I Y N F D E S \* L K L G D L S H K T E E V

350 \* 360 \* 370 \* 380 \* 390 \* 400 \*  
 AAAGAGCCACCAGGATTTTCTCATAATCTCCTTTGGTTTCATCCAGGATGGCTTGGCAAAGGAGATA  
 TTTCTCGGTGTCCTAAAAGAGATATTAGAGGAAACCAAGTAGGTCCTACCGAACCGTTTCCCTCTAT  
 Q R A T R I F S \* S P L V S S R M A W Q R E I >  
 K E P P G F S H N L L W F H P G W L G K G R Y >  
 K' S H Q D F L I I S F G F I Q D G L A K G D >  
 <L S G G P N E \* L R R Q N \* G P H S P L P L Y  
<L A V L C K E Y D G K T E D L I A Q C L S I  
 <F L W W S K R M I E K P K M W S P K A F P S V



~~715-16~~

8/17

410 \* 420 \* 430 \* 440 \* 450 \* 460 \* 470 \*  
 CCATACATCTTCTGATAGAATGCTTTGATATCATTCATGTCAATTTCAGAACGGGAACCATATCCT  
 GGTATGTAGAAGACATCTTACGAAACTATAGTAACTAGTACAGTTAAAGTCTTGCCCTTTGGTATTAGGA  
 P Y I F \* \* N A L I S F M S I S E R E T I I L>  
 H T S S D R M L \* Y H S C Q F Q N G K P \* S>  
 T I H L L I E C F D I I H V N F R T G N H N P>  
 <W V D E S L I S Q Y \* E H \* N \* F P F G Y D Q  
 <G Y M K Q Y F A K I D N M D I E S R S V M I R  
 <M C R R F S H K S I M \* T L K L V P F W L G  
 480 \* 490 \* 500 \* 510 \* 520 \* 530 \* 540 \*  
 GATCAATGCCCTTATGCGAGTCCAAACACCTTTCATGGCTTGATGAAGCTTCTCTGCAAGAAAGCT 5'  
 CTAGTTACGGAATAACGCTCAAGGTGTGGAAGTACCGAACTACTTCGAAGAGACGTTTCTTTCGA 3'  
 I N A L L R V P T P F M A \* \* S F S A K K A>  
 \* S M P Y C E F Q H L S W L D E A S L Q R K L>  
 D Q C L I A S S N T F H G L M K L L C K E S X>  
 <D I G \* S N W C R E H S S S A E R C L F  
 <I L A K N R T G V G K M A Q H L K E A F F A  
 <S \* H R I A L E L V K \* P K I F S R Q L S L



755-1H

9/17



P-40 →

10/17



11/17




FIG. 4

12/17




FIG. 5

13/17





FIG. 6A




WO 99/21980

14/17


## Cytotoxicity assay

FIG. 5B



## Cytotoxicity assay

FIG. 5C





15/17



16/17



17/17



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/CA 98/00992

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12Q1/68 C12N15/11 A61K31/70  
A61K39/395 A61K38/17 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86 04094 A (BIOGEN NV) 17 July 1986 see whole document, example B and sequences in the claims.	1-5,7-11
X	HORSEMAN, N.D. ET AL.: "Cell and species distribution of prolactin-inducible annexin I mRNA" GENERAL AND COMPARATIVE ENDOCRINOLOGY, vol. 85, no. 3, March 1992, pages 405-14, XP002097084	7
A	see abstract; figures 1,3 --- -/--	6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not  
considered to be of particular relevance

"E" earlier document but published on or after the international  
filing date

"L" document which may throw doubts on priority claim(s) or  
which is cited to establish the publication date of another  
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or  
other means

"P" document published prior to the international filing date but  
later than the priority date claimed

"T" later document published after the international filing date  
or priority date and not in conflict with the application but  
showing the state of the art underlying the  
invention

"X" document of particular relevance; the claimed invention  
cannot be considered novel or cannot be considered to  
involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention  
cannot be considered to involve an inventive step when the  
document is combined with one or more other such docu-  
ments, such combination being obvious to a person skilled  
in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 March 1999

Date of mailing of the international search report

07/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/CA 98/00992

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WANG, Y. ET AL.: "Overexpression of a 40-kDa protein in human multidrug resistant cells."  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,  vol. 236, no. 2, 17 July 1997, pages 483-8, XP002097085  cited in the application  see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>BHUSHAN, A. ET AL.: "Increased tyrosinase phosphorylation of lipocortin I in multidrug resistant sarcoma 180 cells."  PROCEEDINGS OF THE 82ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,  vol. 32, no. 0, 15 - 18 May 1991, pages 362-Abstr. 2148, XP002097086  see the whole document</p> <p style="text-align: center;">---</p>	
A	<p>COLE, S.P.C. ET AL.: "Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell."  BRITISH JOURNAL OF CANCER,  vol. 65, no. 4, April 1992, pages 498-502, XP002097087  see abstract  see page 501, left-hand column, paragraph 2 - right-hand column, paragraph 2</p> <p style="text-align: center;">---</p>	
P,X	<p>CAROLLO, M. ET AL.:  "Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin I"  ONCOLOGY RESEARCH,  vol. 10, no. 5, July 1998, pages 245-54, XP002097088  see abstract</p> <p style="text-align: center;">-----</p>	<p>6,7,19,  20</p>

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/ 00992

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 15-17  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00992

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8604094 A	17-07-1986	US 4879224 A	07-11-1989
		US 4874743 A	17-10-1989
		AT 108830 T	15-08-1994
		AU 601676 B	20-09-1990
		AU 5318286 A	29-07-1986
		DE 3689977 D	25-08-1994
		DE 3689977 T	27-10-1994
		DK 433686 A	10-09-1986
		EP 0209568 A	28-01-1987
		FI 863626 A	09-09-1986
		JP 7089996 A	04-04-1995
		JP 7087980 A	04-04-1995
		JP 7101994 A	18-04-1995
		JP 7087789 B	27-09-1995
		JP 62501679 T	09-07-1987
		US 5081019 A	14-01-1989
		US 4950646 A	21-08-1990